



10070611.072202

JC20 Rec'd PCT/PTO 0 8 MAR 2002

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				029976-0101	
				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.52) Not yet assigned	
INTERNATIONAL APPLICATION NO. PCT/EP00/08863		INTERNATIONAL FILING DATE 09/11/2000		PRIORITY DATE CLAIMED 09/09/1999	
TITLE OF INVENTION A MINIMAL TAU PEPTIDE FOR THE NUCLEATION OF PAIRED HELICAL FILAMENTS					
APPLICANT(S) FOR DO/EO/US Martin von BERGEN, Jacek BIERNAT, Eva-Marie MANDELKOW and Eckhard MANDELKOW.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.	<input checked="" type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2.	<input type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4.	<input checked="" type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.			
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
	<input type="checkbox"/>	is transmitted herewith (required only if not transmitted by the International Bureau).			
	<input checked="" type="checkbox"/>	has been transmitted by the International Bureau.			
	<input type="checkbox"/>	is not required, as the application was filed in the United States Receiving Office (RO/US)			
6.	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7.	<input checked="" type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
	<input type="checkbox"/>	are transmitted herewith (required only if not transmitted by the International Bureau).			
	<input type="checkbox"/>	have been transmitted by the International Bureau.			
	<input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.			
	<input checked="" type="checkbox"/>	have not been made and will not be made.			
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9.	<input type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
11.	<input type="checkbox"/>	Applicant claims small entity status under 37 CFR 1.27.			
Items 12. to 17. below concern other document(s) or information included:					
12.	<input checked="" type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98 and form PTO-1449.			
13.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
14.	<input checked="" type="checkbox"/>	A FIRST preliminary amendment.			
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.			
15.	<input type="checkbox"/>	A substitute specification.			
16.	<input type="checkbox"/>	A change of power of attorney and/or address letter.			
17.	<input checked="" type="checkbox"/>	Other items or information: Application Data Sheet (4 pages), copy of the as-filed application (specification 56 pages; 22 sheets of drawings (Figs. 1-9); and Paper Copy of Sequence Listing 13 pages) and Copy of the International Search Report (2 pages).			



JC13 Rec'd PCT/PTO 08 MAR 2002

U.S. APPLICATION NO. (Unknown, see 37 CFR 1.50) Unassigned 107070611		INTERNATIONAL APPLICATION NO. PCT/EP00/08863		ATTORNEY'S DOCKET NUMBER 029976-0101	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$890.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$710.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))				\$130.00	
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	27	- 20	= 7	× \$18.00	\$126.00
Independent Claims	5	- 3	= 2	× \$84.00	\$168.00
Multiple dependent claim(s) (if applicable)				\$280.00	
TOTAL OF ABOVE CALCULATIONS =				\$1314.00	
Reduction by ½ for filing by small entity, if applicable.				\$0.00	
SUBTOTAL =				\$1314.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$1314.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				+	
TOTAL FEES ENCLOSED =				\$1314.00	
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1314.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$_____ to the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Foley & Lardner Customer Number: 22428			 SIGNATURE <u>Reg. No. 29,768</u> NAME RICHARD C. PEET REGISTRATION NUMBER 35,792		
 22428 PATENT TRADEMARK OFFICE					

JC13 Rec'd PCT/PTO 08 MAR 2002

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				029976-0101	
INTERNATIONAL APPLICATION NO. PCT/EP00/08863		INTERNATIONAL FILING DATE 09/11/2000		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.52) Not yet assigned 10/070611	
PRIORITY DATE CLAIMED 09/09/1999					
TITLE OF INVENTION A MINIMAL TAU PEPTIDE FOR THE NUCLEATION OF PAIRED HELICAL FILAMENTS					
APPLICANT(S) FOR DO/EO/US Martin von BERGEN, Jacek BIERNAT, Eva-Marie MANDELKOW and Eckhard MANDELKOW.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. <input type="checkbox"/> Applicant claims small entity status under 37 CFR 1.27 . Items 12. to 17. below concern other document(s) or information included: 12. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 and form PTO-1449. 13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> Other items or information: Application Data Sheet (4 pages) , copy of the as-filed application (specification 56 pages; 22 sheets of drawings (Figs. 1-9); and Paper Copy of Sequence Listing 13 pages) and Copy of the International Search Report (2 pages).					

JG13 Rec'd PCT/PTC 08 MAR 2002

U.S. APPLICATION NO. (If known, see 37 CFR 1.550) Unassigned 107070611		INTERNATIONAL APPLICATION NO. PCT/EP00/08863		ATTORNEY'S DOCKET NUMBER 029976-0101	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$890.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482)\$710.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))				\$130.00	
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	27	-	20	= 7 x \$18.00	\$126.00
Independent Claims	5	-	3	= 2 x \$84.00	\$168.00
Multiple dependent claim(s) (if applicable)				\$280.00	
TOTAL OF ABOVE CALCULATIONS =				\$1314.00	
Reduction by 1/2 for filing by small entity, if applicable.				\$0.00	
SUBTOTAL =				\$1314.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$1314.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =				\$1314.00	
				Amount to be: refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$1314.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$_____ to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Foley & Lardner Customer Number: 22428			 SIGNATURE <u>Reg. No. 29,768</u> NAME RICHARD C. PEET REGISTRATION NUMBER 35,792		
 22428 PATENT TRADEMARK OFFICE					

Atty. Dkt. No. 029976-0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: von Bergen et al.
Title: A MINIMAL TAU PEPTIDE FOR THE NUCLEATION OF PAIRED
HELICAL FILAMENTS
Appl. No.: Not yet assigned
Appl. Filing Date: concurrently herewith
Examiner: Not yet assigned
Art Unit: Not yet assigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Prior to examination of the present National Phase Application, Applicants respectfully request that the application be amended as follows:

In the Claims:

Please cancel claims 1-27 without prejudice or disclaimer and insert the following new claims.

28. (New) A method for identifying and obtaining an inhibitor, capable of modifying the paired helical filaments (PHF) formation comprising the steps of:
- (a) incubating a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 and 9 or (a) fragment(s) thereof, with a compound to be screened under conditions which permit assembly of said tau-derived peptide into nucleation sites for PHF assembly and/or into aggregation products; and
 - (b) detecting the presence, decrease, or absence of nucleation sites for PHF assembly, and/or the presence, decrease or absence of aggregation

products, wherein said absence and/or decrease of is indicative of putative inhibitors of PHF formation.

29. (New) The method of claim 28, wherein said incubation step is carried out in the presence of assembly-competent tau protein(s) and/or assembly-competent tau protein fragments and wherein in step (b) the presence, decrease and/or absence of PHF or tau filaments is detected.
30. (New) A method for identifying and obtaining an inhibitor of PHF formation comprising:
 - (a) contacting a peptide comprising a specific tau-derived peptide as defined in any one of SEQ ID NOs. 6, 7, 8 or 9 or (a) fragment(s) thereof with a first molecule known to bind to said peptide to form a first complex of said peptide and said first molecule;
 - (b) contacting said first complex with a compound to be screened; and
 - (c) measuring whether said compound displaces said first molecule from said first complex.
31. (New) The method of claim 30, wherein said measuring step (c) comprises the measurement of a formation of a second complex of said tau-derived peptide and said compound.
32. (New) The method of claim 30, wherein said measuring step (c) comprises the measurement of the amount of said first molecule that is not bound to said tau-derived peptide.
33. (New) A method for the preparation of a pharmaceutical composition comprising the putative inhibitors for PHF formation identified, obtained and/or screened in step (b) of claim 28 or derivatives thereof, in a pharmaceutically acceptable form by synthesizing and/or formulating said inhibitors.
34. (New) The method of claim 28, said peptide comprising a tau-derived peptide is bound to a solid phase.
35. (New) The method of claim 28, wherein said incubation step is carried out in the presence of (poly)anions.

36. (New) An inhibitor identified or obtained by the method of claim 28.
37. (New) The inhibitor of claim 36 which specifically binds to a peptide comprising the tau-derived peptides as defined in any one of SEQ ID NOs. 6, 7, 8 or 9 or (a) fragment thereof.
38. (New) The inhibitor of claim 37 which is an antibody, an aptamer or a small molecule peptide.
39. (New) The inhibitor of claim 38 which is a monoclonal antibody.
40. (New) A composition comprising the inhibitor as claim 36.
41. (New) The composition of claim 40, which is a diagnostic or a pharmaceutical composition further comprising, optionally, suitable means of detection and/or a pharmaceutically acceptable carrier, excipient and/or diluent.
42. (New) A method for detecting and/or measuring PHF formation comprising the steps of:
 - (a) incubating a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs. 6, 7, 8 or 9 or (a) fragment(s) thereof, with tau-protein(s) and/or fragments thereof under conditions which permit assembly of tau-proteins and/or fragments thereof into PHFs; and
 - (b) detecting the presence, absence, decrease or increase of PHFs and/or nucleation sites of PHF assembly.
43. (New) The method of claim 42, wherein said detection or measuring step is carried out by microscopical or spectroscopical means.
44. (New) The method of claim 43, wherein said microscopical means comprises electron microscopy.
45. (New) The method of claim 43, wherein said spectroscopical means comprises circular dichroism spectroscopy or fluorescence spectroscopy, or infrared spectroscopy.

46. (New) The method of claim 45, wherein said fluorescence spectroscopy comprises a thioflavin S or T assay or a tyrosine self-fluorescence assay.
47. (New) A kit useful for identifying an inhibitor capable of modifying the PHF formation comprising at least one of the following:
- (a) a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOS 6, 7, 8 or 9 or (a) fragment(s) thereof and/or a nucleic acid molecule encoding said peptide or (a) fragment(s) thereof;
 - (b) assembly-competent tau-protein(s) and/or fragments thereof; and
 - (c) a solid support to which said peptide is bound;
- said kit optionally further comprising a standard and/or suitable means for detection of said inhibitor.
48. (New) A kit comprising an inhibitor of PHF formation of claim 36 or a composition comprising said inhibitor.
49. (New) A method of claim 28, wherein said specific tau derived peptide is expressed in a test system by a nucleic acid molecule.
50. (New) A method of claim 49, wherein said test system comprises a nucleic acid molecule encoding at least one of said specific tau derived peptide as defined in at least one of SEQ ID Nos. 6, 7, 8 and 9.
51. (New) A method of claim 50, wherein said peptide comprising a specific tau derived peptide as defined in at least one of SEQ ID NOS. 6, 7, 8 and 9 is expressed in a test system comprising a non-human transgenic animal, a tissue culture and/or a cell culture system.
52. (New) A method of claim 28, wherein said peptide comprises a specific tau derived peptide as defined in at least one of SEQ ID NOS 6, 7, 8 and/or 9, and wherein a hexapeptide as defined in SEQ ID NOS 7 or 8 is used, then at least one mutation and/or modification is present in SEQ ID NOS 7 or 8.

Atty. Dkt. No. 029976-0101

53. (New) A method of claim 52, wherein said mutation and/or modification comprises the replacement of at least one amino acid with high intrinsic β -sheet propensity with at least one amino acid with low or no intrinsic β -sheet propensity.
54. (New) A nucleic acid molecule encoding a specific tau derived peptide as defined in SEQ ID Nos. 6, 7, 8 or 9.

REMARKS

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application to delete improper multiple dependencies.

Claims 1-27 have been canceled and claims 28-54 have been added as set forth above. Therefore, claims 28-54 are now pending in this application.

Applicants believe that the present application is now in condition for allowance. Favorable consideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date 8 March 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

By S. G. Peet, Reg #29,768

for Richard C. Peet
Attorney for Applicant
Registration No. 35,792

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Martin von Bergen et al.
Title: A MINIMAL TAU PEPTIDE FOR THE NUCLEATION OF
 PAIRED HELICAL FILAMENTS
Appl. No.: 10/070/611
Appl. Filing Date: July 22, 2002
Examiner: Not yet assigned
Art Unit: Not yet assigned

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the present National Phase Application, Applicants respectfully request that the application be amended as follows:

In the Specification:

On page 27, delete the 2nd full paragraph, and replace this paragraph with the following in accordance with 37 CFR §1.121. A marked up version showing changes is attached:

Fig. 1 Bar diagram of tau constructs and peptides. (a) htau40, the longest isoform in the human CNS, containing four repeats of ~31 residues (labeled 1-4) and two inserts near the N-terminus. Residue numbering follows that of htau40 throughout. (b) htau23, the smallest and fetal isoform, lacking the N-terminal inserts and repeat R2. (c) K19 represents only the repeat domain of htau23, i.e. R1, R3, R4 (i.e. 94 residues, Q244-N368, but without V275-S305). (d) PHF43, a subfragment of K19, containing the end of R1, all of R3, and the beginning of R4, but without R2 (43 residues) (SEQ ID NO:6). (e) PHF8, 8 residues spanning the junction between R1 and R3 (SEQ ID NO:9). (f) PHF6, 6 residues from the

Atty. Dkt. No. 029976-0101

beginning of R3 (SEQ ID NO:8). The other peptides (V318-K321 (SEQ ID NO:14), V318-G335 (SEQ ID NO:15) and G335-E342 (SEQ ID NO:16)) span the PHF43 sequence and were used for analysis by CD. (SEQ ID NOS:60-62 are also shown in this figure.)

On page 28, delete the 1st full paragraph, and replace this paragraph with the following in accordance with 37 CFR §1.121. A marked up version showing changes is attached:

Fig. 3: Peptides derived from tau and their ability for PHF assembly.

The peptide K19 contains the repeats 1, 3, and 4 of tau, but repeat 2 (exon 10) is absent, as in the fetal human isoform tau23 (see Fig. 1). In the standard numbering according to htau40, the longest isoform in the human CNS, K19 extends from residue 244 to 368, but lacking the 31 residues 275-305 (which in 4-repeat isoforms would be inserted after K275, labeled with an asterisk). Each repeat terminates with a characteristic PGGGX motif. Mutations of K19 (K19^{ΔVQI} (SEQ ID NO:13), K19^{NAB} (SEQ ID NO:11) and K19^{Y310E} (SEQ ID NO:12)) are indicated below the K19 sequence (SEQ ID NO:10). Chymotrypsin cleaves K19 after Y310 and F345 and thus cuts the minimal interaction motif in two parts. GluC at pH 4.0 cleaves K19 after E264, E337 and E342, leading to four fragments as defined in SEQ ID NOS: 52, 6, 53 and 54. This generates the 43 residue peptide PHF43 (underlined, N265-E337 without the second repeat; see also SEQ ID NO:6). GluC at pH 7.8 cleaves K19 after D252, E264, D314, and E337, leading to five fragments as depicted also in SEQ ID NOS:55 to 59. It cleaves PHF43 into two halves but leaves the minimal interaction motif intact (see also SEQ ID NO:57). Other synthetic peptides are listed below: PHF6 (SEQ ID NO: 8), PHF8 (SEQ ID NO: 9), V313-K321 (SEQ ID NO: 17), V318-G335 (SEQ ID NO: 18), G335-E342 (SEQ ID NO: 19). As demonstrated in the appended examples, fragments comprising the minimal VQIVYK motif (SEQ ID NO:8) are capable of specific aggregation (asterisk) and/or the formation of nucleation sides for PHF formation (+).

Atty. Dkt. No. 029976-0101

On page 29, delete the 1st full paragraph, and replace this paragraph with the following in accordance with 37 CFR §1.121. A marked up version showing changes is attached:

Fig. 5: Peptide spot membrane interactions between PHF43 and peptides derived from the repeat region of tau.

The region of tau from L253 in repeat 1 to D348 in repeat 4 (encompassing the sequence of PHF43) was subdivided into consecutive 15-mer peptides staggered by 3 residues (SEQ ID NOS:22-51), synthesized and covalently attached to a cellulose membrane (Frank, J. Biotechnol. 41 (1995), 259-272), and incubated with iodinated PHF43. The bars represent the bound radioactivity determined by autoradiography. The strongest interaction occurs around spot 4-25 which contains the sequence of PHF6 (VQIVYK, bold) at the beginning of R3. Another cluster of strong interaction occurs around spot 4-16 which harbors the analogous sequence in R2 (VQIINK, bold).

Atty. Dkt. No. 029976-0101

REMARKS

In regard to the above amendments to the specification, SEQ ID NO designations are added to the specification based upon matching the sequences in the specification with the corresponding sequences in the Sequence Listing filed concurrently herewith. No new matter is added.

Applicants believe that the present application is now in condition for allowance. Favorable consideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date

July 22, 2002

FOLEY & LARDNER

Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407

Facsimile: (202) 672-5399

By

Richard C. Peet
Reg. No. 34,485

Richard C. Peet

Attorney for Applicants

Registration No. 35,792

Marked-up Specification:***Page 27, 2nd paragraph:***

Fig. 1 Bar diagram of tau constructs and peptides. (a) htau40, the longest isoform in the human CNS, containing four repeats of ~31 residues (labeled 1-4) and two inserts near the N-terminus. Residue numbering follows that of htau40 throughout. (b) htau23, the smallest and fetal isoform, lacking the N-terminal inserts and repeat R2. (c) K19 represents only the repeat domain of htau23, i.e. R1, R3, R4 (i.e. 94 residues, Q244-N368, but without V275-S305). (d) PHF43, a subfragment of K19, containing the end of R1, all of R3, and the beginning of R4, but without R2 (43 residues) (SEQ ID NO:6). (e) PHF8, 8 residues spanning the junction between R1 and R3 (SEQ ID NO:9). (f) PHF6, 6 residues from the beginning of R3 (SEQ ID NO:8). The other peptides (V318-K321 (SEQ ID NO:14), V318-G335 (SEQ ID NO:15) and G335-E342 (SEQ ID NO:16)) span the PHF43 sequence and were used for analysis by CD. (SEQ ID NOS:60-62 are also shown in this figure.)

Page 28, 1st paragraph:**Fig. 3: Peptides derived from tau and their ability for PHF assembly.**

The peptide K19 contains the repeats 1, 3, and 4 of tau, but repeat 2 (exon 10) is absent, as in the fetal human isoform tau23 (see Fig. 1). In the standard numbering according to htau40, the longest isoform in the human CNS, K19 extends from residue 244 to 368, but lacking the 31 residues 275-305 (which in 4-repeat isoforms would be inserted after K275, labeled with an asterisk). Each repeat terminates with a characteristic PGGGX motif. Mutations of K19 (K19^{ΔVQI} (SEQ ID NO:13), K19^{NAE} (SEQ ID NO:11) and K19^{Y310E} (SEQ ID NO:12)) are indicated below the K19 sequence (SEQ ID NO:10). Chymotrypsin cleaves K19 after Y310 and F345 and thus cuts the minimal interaction motif in two parts. GluC at pH 4.0 cleaves K19 after E264, E337 and E342, leading to four fragments as defined in SEQ ID NOS: 52, 6, 53 and 54. This generates the 43 residue peptide PHF43 (underlined, N265-E337 without the second repeat; see also SEQ ID NO:6). GluC at pH 7.8 cleaves K19 after D252, E264, D314, and E337, leading to five fragments as depicted also in SEQ ID NOS:55 to 59. It cleaves PHF43 into two halves but leaves the minimal interaction motif intact (see also SEQ ID NO:57). Other synthetic peptides are listed below: PHF6

Atty. Dkt. No. 029976-0101

(SEQ ID NO: 8), PHF8 (SEQ ID NO: 9), V313-K321 (SEQ ID NO: 17), V318-G335 (SEQ ID NO: 18), G335-E342 (SEQ ID NO: 19). As demonstrated in the appended examples, fragments comprising the minimal VQIVYK motif (SEQ ID NO:8) are capable of specific aggregation (asterisk) and/or the formation of nucleation sides for PHF formation (+).

Page 29, 1st paragraph:

Fig. 5: Peptide spot membrane interactions between PHF43 and peptides derived from the repeat region of tau.

The region of tau from L253 in repeat 1 to D348 in repeat 4 (encompassing the sequence of PHF43) was subdivided into consecutive 15-mer peptides staggered by 3 residues (SEQ ID NOS:22-51), synthesized and covalently attached to a cellulose membrane (Frank, J. Biotechnol. 41 (1995), 259-272), and incubated with iodinated PHF43. The bars represent the bound radioactivity determined by autoradiography. The strongest interaction occurs around spot 4-25 which contains the sequence of PHF6 (VQIVYK, bold) at the beginning of R3. Another cluster of strong interaction occurs around spot 4-16 which harbors the analogous sequence in R2 (VQIINK, bold).

10070611 072202



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/070,611	Martin Von Bergen	029976-0101

INTERNATIONAL APPLICATION NO.

PCT/EP00/08863

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

09/11/2000

22428
FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

CONFIRMATION NO. 9060

371 FORMALITIES LETTER



OC00000008152602

Date Mailed: 05/20/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Preliminary Amendments

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DARRELL C COTTMAN

Telephone: (703) 305-3693

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/070,611	PCT/EP00/08863	029976-0101

22/p.s.

New PCT application
Our Ref.: D 1894 PCT

A minimal tau peptide for the nucleation of paired helical filaments

The present invention relates to a method for identifying and obtaining an inhibitor, capable of modifying the PHF ("paired helical filaments") formation comprising the steps of (a) incubating a peptide comprising a specific tau derived peptide as defined herein or a fragment(s) thereof with a compound to be screened under conditions which permit assembly of said tau-derived peptides into nucleation sites for PHF assembly and/or into aggregation products; and (b) detecting the presence, decrease, or absence of nucleation sites for PHF assembly and/or the presence, decrease or absence of said aggregation products wherein said absence and/or decrease is indicative for putative inhibitors for PHF formation. Furthermore, the present invention provides inhibitors identified or obtained by said method as well as compositions comprising said inhibitor, wherein said composition is preferably a diagnostic and/or a pharmaceutical composition. The present invention further relates to a method for detecting and/or measuring PHF formation comprising the steps of (a) incubating a peptide comprising a specific tau derived peptide as defined herein or (a) fragment(s) thereof, with tau-proteins and/or fragments thereof under conditions which permit assembly of tau-proteins and/or fragments thereof into PHFs; and (b) detecting the presence, absence, decrease or increase of PHFs and/or nucleation sites of PHF assembly.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated by reference; however, there is no admission that any document cited is indeed prior art of the present invention.

Alzheimer's disease and other dementias are characterized by abnormal protein deposits in the brain, such as amyloid plaques or neurofibrillary tangles, formed by fibrous assemblies of the A β peptide or of tau protein, wherein these tangles

comprise tau protein aggregated into so-called paired helical filaments (PHFs) as reviewed in Lee and Trojanowski (1992), *Curr. Opin. Neurobiol.* 2, 653-656. These aggregates are thought to be toxic to neurons, either by causing some toxic signaling defect (in the case of A β) or by obstructing the cell interior (in the case of tau deposits). It is therefore one of the top priorities in Alzheimer research to understand the reasons for the pathological aggregation in order to find methods to prevent it. The principles governing A β aggregation are understood in some detail: The peptide (40-43 residues) is a short derivative of a much larger membrane protein (APP) which is cleaved in an inappropriate fashion (by β and γ secretases); the peptide is largely hydrophobic because it contains the membrane insertion sequence which tends to promote aggregation, and it undergoes a conformational change to a β -conformation which allows fiber assembly with a "cross β " interaction (Barrow, *J. Mol. Biol.* 225 (1992), 1075-1093; Hilbich, *J. Mol. Biol.* 228 (1992), 460-473; Jarrett and Lansbury, *Cell* 74 (1993), 1055-1058; Kirschner, *Proc. Natl. Acad. Sci. USA* 83 (1986), 503-507). A similar cross- β structure is found in other disease-related proteins, such as fibrous prion protein (in Creutzfeld-Jacob disease) or transthyretin fibers (in systemic amyloidosis, reviews Castano and Frangione, *Curr. Opin. Neurology* 8 (1995), 279-285; Lansbury, *Proc. Natl. Acad. Sci. USA* 96 (1999), 3342-3344).

By contrast, the principles governing tau aggregation have remained elusive (review, Friedhoff & Mandelkow, 1999). Tau is not only soluble and displays a 'natively unfolded' structure (as mentioned, *inter alia*, in Mandelkow (1998), *TICB* 8, 425-427), but is one of the most hydrophilic proteins known, a fact that strongly argues against hydrophobic interactions. Tau can aggregate as an intact protein, 352-441 residues in length (depending on isoform), so that all 6 tau isoforms are found in Alzheimer paired helical filaments (PHFs) (Goedert, *Neuron* 8 (1992), 159-168). PHFs are therefore made up of tau protein, forming the neurofibrillary tangles. In tau, there are either 0, 1, or 2 inserts of 29 residues each near the N-terminus, and 3 or 4 homologous stretches of 31 residues each, the "repeats" in the C-terminal half (repeat R2 may be missing). Thus, the longest isoform has four repeats and two inserts, the shortest (fetal) isoform has 3 repeats and no inserts. The 4 repeats are followed by a poorly conserved "fifth" repeat (R'). A "big tau" isoform

containing ~300 additional residues (exon 4a) is expressed in peripheral nerves (Couchie, Proc. Natl. Acad. Sci. USA 89 (1992), 4378-4381). Tau contains either one or two cysteines, residue 322 in repeat 3 (always present), and residue 291 in repeat 2 (present only in 4-repeat isoforms). This difference has an influence on PHF assembly. As mentioned herein above, the amino acid composition of tau is dominated by hydrophilic and charged residues, an acidic stretch near the N-terminus followed by mostly basic domains. The repeats are flanked by regions rich in prolines. The C-terminal half of tau (repeats plus flanking regions) constitutes the microtubule-binding domain. The core of the above-mentioned PHFs (paired helical filaments) are mainly built from the repeat domain (Ksiezak-Reding and Yen, Neuron 6 (1991), 717-728; Novak, EMBO J. 12 (1993), 365-370; Wischik, Proc. Natl. Acad. Sci. USA (1988), 4506-4510), and this domain also promotes PHF assembly in vitro (Wille, J. Cell Biol. 118 (1992), 573-584). Tau contains almost no secondary structure but rather appears as a Gaussian random coil, as judged by spectroscopic and X-ray evidence (Cleveland, J. Mol. Biol. 116 (1977), 227-247). These data thus provide no basis for making assumptions about secondary structure interactions. Additionally, as e.g. shown in Schweers (1994), JBC 269, 24290-24297, tau protein behaves in solution as if it were denatured and no evidence for compact folding was detected. Schweers and colleagues employed a variety of spectroscopy methods in order to elucidate the conformation of tau protein and PHFs and came to the conclusion that it is unlikely that the aggregation of tau into Alzheimer PHFs is based on interactions between strands of β -sheets (a model currently favored for other disease-related polymers such as β -amyloid fibers of Alzheimer's disease). Therefore, the nature of the PHF (and/or tau) aggregation mechanism could not simply be modeled on the basis of known protein structures. On the other hand, despite its random coil appearance in solution, tau assembles into a well-defined periodic fiber, the paired helical filament (PHF). This process can be enhanced by oxidation (Wille (1992), loc. cit.), by polyanions (Friedhoff, Biochemistry 37 (1998a), 10223-10230; Goedert, Nature 383 (1996), 550-553; Kampers, FEBS Letters 399 (1996), 344-349; Perez, J. Neurochem. 67 (1996), 1183-1190) and can be described by a nucleation-condensation mechanism (Friedhoff, Proc. Natl. Acad. Sci. USA 95 (1998b), 15712-15717). Here, too, the secondary structure content is below detectability (Schweers, J. Biol. Chem. 269

(1994), 24290-24297). A fraction of tau polymers in Alzheimer brains occurs as straight (untwisted) fibers (Crowther, Proc. Natl. Acad. Sci. USA (1991), 2288-2292), and fibers without axial periodicity have also been described for some in vitro assembly conditions (Montejo de Garcini and Avila, J. Biochem. 102 (1987), 1415-1421; Perez, loc. cit.; Wilson and Binder, Amer. J. Pathol. 150 (1997), 2181-2195).

Because of the long-range periodicity of most PHFs it can be speculated that they are built from a reproducible secondary structure element in the microtubule-binding domain of tau which is responsible for the repetitive and specific interaction that leads to filament aggregation. However, said secondary structure was not yet elucidated and this secondary structure element might be too short to be detected by global spectroscopic studies of intact tau. As mentioned herein above, tau was illustrated as a "Gaussian" polymer and no unique folding was deduced so that many different structures are possible. The relevant structural element might be too short to be detected reliably by global spectroscopic studies of intact tau.

Additionally, PHFs form much more easily from tau constructs containing only the repeat region than from whole tau. Schweers showed in 1995 (Proc. Natl. Acad. Sci. USA 92, 8463-8467) that the repeats are necessary for assembling PHFs in vitro. A SH group in repeat 3 was described to be available for forming intermolecular disulfide linkages and this initial dimerization was considered as the basis for further PHF assembly.

There is a widespread feeling in the art that in general pathologic fibers tend to be "amyloidogenic" in nature, meaning that they consist of proteins with predominant β -structure which leads to the irreversible aggregation. However, in the case of tau, Mandelkow (Neurobiology of Aging 16, 347-354) mentions that in spectrometric experiments no CD-spectrum expected for a protein with β -conformation could be detected when several tau isoforms or constructs derived from them were evaluated. Therefore, it was concluded that fiber aggregation on the basis of β -strand interaction is unlikely in the case of tau, in contrast to the aggregation of β -amyloid.

All previous art, therefore, showed that the repeat region of tau might be involved in

PHF nucleation formation and/or aggregation, however, a distinct structural feature of tau which might be responsible for said PHF nucleation formation and/or aggregation was not described. Additionally, genetically engineered constructs were employed in in vitro assays to show that PHFs can arise from a nucleated assembly mechanism which is dependent on the dimerization of tau (Friedhoff, 1998, loc. cit.). However, said in vitro assays provided no insight in the minimal requirements for nucleation, formation of PHFs and/or aggregation of tau protein or tau peptides. Furthermore, test assays and systems for PHF assembly, as described in the prior art and based on full-length tau (see, inter alia, Wille (1992), loc. cit.) or on fragments thereof, comprising major parts of the repeat-domain of tau (e.g. the peptide K19 as described in the appended examples or, inter alia, in Friedhoff (1998), loc. cit.) need incubation times for PHF assembly which vary from several minutes up to several days. These prior art assays involve the addition of polyanions, like heparin, poly-glutamic acid or RNA and oxidation of SH-groups on the tau protein or the corresponding fragments.

Considering the fact that tau aggregation is much less understood than that of, inter alia, β -amyloid, and even counter-intuitive since tau is cytosolic and one of the most highly soluble proteins known in the art, it is not clear why tau should aggregate in a specific manner to form Alzheimer related PHFs. Furthermore, it is unknown which specific structural principle could be responsible for PHF formation and/or aggregation. Additionally, prior test systems and methods, based on full-length tau or fragments thereof comprising the repeat domain are rather slow and are not capable of providing for fast and reliable assays for PHF formation and/or aggregation of tau or tau derived peptides. Said desired fast and reliable test assays may be used, inter alia, for the testing of potential drugs which may interfere with the above described pathological tau assembly. Accordingly, means and methods for diagnosing and treating Alzheimer's disease on the basis of said structural principle of tau, e.g. with chemotherapeutic treatment of said disease which influences tau aggregation, were hitherto not available but are nevertheless highly desirable.

Thus, the technical problem of the present invention is to comply with the needs described above. The solution to this technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the invention relates to a method for identifying and obtaining an inhibitor, capable of modifying the PHF formation comprising the steps of

- (a) incubating a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 and 9 or (a) fragment(s) thereof, with a compound to be screened under conditions which permit assembly of said tau derived peptides into nucleation sites for PHF assembly and/or into aggregation products; and
- (b) detecting the presence, decrease, or absence of nucleation sites for PHF assembly and/or the presence, decrease or absence of said aggregation products wherein said absence and/or decrease is indicative for putative inhibitors for PHF formation.

The term "PHF formation" as used in accordance with this invention means the assembly of tau protein or fragments thereof into paired helical filaments, wherein said paired helical filaments do not only comprise bona fide PHFs but also thin filaments of tau protein or fragments thereof which may serve as nuclei and/or nucleation sites which can efficiently promote the assembly of bona fide PHFs from tau fragments, tau constructs and/or intact tau. For example, the aggregation of smaller tau derived peptides (like PHF43, SEQ ID NO: 6) as described herein (see appended examples) into thin filamentous structures or nucleation sites for PHFs is also considered as "PHF formation". Furthermore, the term "PHF formation" comprises also PHF aggregations and aggregation of peptides comprising tau-fragments. The aggregation of said peptides comprising a specific tau derived peptide as defined herein as well as the dimerization of said peptide is also comprised in said term. Similarly, the term "aggregation products" comprises any aggregation, interaction, assembly and/or dimerization of said peptides. Said "aggregation products" may be measured during their formation and/or as final reaction product. Methods for the measurement of PHF formation and/or the formation of aggregation products are well known in the art and described, inter alia, in the appended examples.

The term "modifying the PHF formation" as used herein is not limited to (complete) "inhibiting" but also comprises "delaying" the PHF formation under suitable in vitro conditions. Such suitable in vitro conditions are known in the art and described, inter

alia in Schweers, Proc. Natl. Acad. Sci. USA 92 (1995), 8463-8467, in Friedhoff, Biochemistry 37 (1995), 10223-10230 or in the appended examples. The term furthermore comprises the alteration which may occur during PHF-nucleation, PHF-elongation or even during first dimerization processes which may lead to a nucleation site for PHF formation. A "modified PHF formation" may be measured, inter alia, by testing said PHF-formation in an assay comprising the compound to be screened and in a parallel assay wherein, under the same in vitro conditions, said compound is omitted and/or replaced by an irrelevant compound, like, lysozyme, BSA, tubulin, hemoglobin, etc.

The term "a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs" means in accordance with the present invention any peptide comprising the specific amino acid sequence as depicted in the corresponding SEQ ID NOs. Preferably, said sequence(s) is (are) derived from the repeat region of tau. Most preferably, said sequences are derived from the sequence stretch between amino acid 244 to 368 (comprising essentially the whole repeat region of the tau isoforms; numbering of human fetal tau). Particularly preferred, in this context, is a tau-derived peptide fragment comprising only 43 residues, i.e. essentially the third repeat plus flanking stretches on either site (human fetal tau sequence 265 to 338 without the second repeat 275-305). Most particularly preferred said peptide comprises the hexapeptide "PHF6", derived from the human fetal tau sequence 306 to 311 (SEQ ID NO: 8), or the hexapeptide "PHF6*", derived from the human fetal tau sequence 275 to 280 (SEQ ID NO: 7). Another peptide comprising a specific tau derived peptide as defined herein above is, inter alia, shown in SEQ ID NO: 9 and denoted as "PHF8". As defined in the appended examples, said peptide comprises the amino acid sequence as depicted in SEQ ID NO: 8 and two additional amino acids (G and K) derived from the neighbouring amino acid sequence of SEQ ID NO: 8 in the full-length human tau sequence. Additionally, the term further comprises (a) peptide(s) or (a) (poly)peptide(s) which encompass amino acid chains of any length, wherein the amino acid residues are linked by covalent peptide bonds. These (poly)peptides, therefore, may consist entirely of the peptides as defined in the corresponding SEQ ID NOs 6, 7, 8 and 9 or may contain additional sequences. The additional sequences may (but need not) be sequences derived from tau protein,

cytoskeletal proteins, microtubule associated proteins and/or microtubule binding proteins. Preferably, said amino acid chains comprises at least 6 amino acids, more preferably said amino acid chain comprises at least 8 amino acids, more preferably at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20, more preferably at least 30, more preferably at least 40, even more preferably at least 45 and even more preferably at least 50, at least 60, at least 70, or at least 80. However, particularly preferred is an amino acid chain comprising 6, 8 or 43 amino acids. In a particularly preferred embodiment said amino acid chain is the amino acid sequence as represented in SEQ ID NO: 6 comprising the amino acid sequence as represented in SEQ ID NO: 8 as well as amino acid sequences derived from tau. The term "or (a) fragment(s) thereof" in (a), supra, means in accordance with the present invention a peptide comprising a specific tau derived peptide fragment as defined in any one of the SEQ ID NOs 6, 7 or 8.

Within the scope of the present invention are also peptides comprising tau derived peptides which are homologous to the above described peptides as depicted in SEQ ID NOs: 6 to 9, but are derived from different species than human. Especially preferred tau homologues are in this context tau-derived peptides from mouse, rat, cow, sheep, polar bear, etc. Furthermore, the present invention also relates to methods, compositions, uses and kits wherein said peptide comprising (a) tau derived peptide(s) is a peptide which is similar to the above described peptides, but wherein said amino acids V, Q and/or I (Valine, Glutamine, Isoleucine) have been replaced, either alone or in combination, by other amino acids which show high intrinsic β -sheet propensities. These amino acids comprise, inter alia T, F, Y (Threonine, Phenylalanine, Tyrosine). Amino acids having a high intrinsic β -sheet propensity are well known in the art and described, inter alia, in Street, (1999), P.N.A.S. 96, 9074-9076. Amino acids which do not have an intrinsic β -sheet propensity, like Proline (P), are also known in the art and can, accordingly, not replace any of the amino acids as defined in the hexapeptide as disclosed herein and depicted in SEQ ID NO: 7 or 8 in order to obtain an assembly competent minimal tau protein/peptide. Therefore, within the scope of the present invention, are also methods and uses wherein functional homologues of the amino acid molecules as depicted in SEQ ID NOS. 6 to 9 are employed. Said functional homologues may comprise, inter alia, the above-mentioned amino acids T, F or Y or other amino

acids having a high intrinsic β -sheet propensity. Yet, it is furthermore envisaged that the the above mentioned amino acids, which do not have intrinsic β -sheet propensity, may be employed in specific tests and methods. It is, e.g. envisaged that one or more amino acids having high intrinsic β -sheet propensity be replaced in the hexapeptide structure as disclosed in SEQ ID NOS 7 or 8 and that said replacement(s) lead(s) to minimal-tau peptides with limited or no β -structure formation capacities. Such "mutated" minimal-tau peptides are particularly useful in animal and/or tissue or cell culture systems or in vitro systems as described herein. It is, e.g., envisaged that in the hexapeptides as described herein, the V, Q and/or I is replaced by N, A and/or E (see also appended examples and Fig. 3) or that (a) single residue(s) in the hexapeptide stretch is/are replaced by proline(s). It is understood that such a replacement may be performed in any minimal-tau peptide as disclosed herein; i.e. minimal-tau peptides as depicted in any of SEQ ID NOS 6 to 9 or in peptides comprising said minimal-tau peptides. Furthermore, it is within the scope of the present invention that even tau full-length tau protein, peptides known in the art, like, inter alia the K18 or K19 stretch, be mutated/modified in the hexapeptide region as disclosed herein (SEQ ID NOS 7 or 8) and that said modified tau protein, or fragments thereof, comprising said modified hexapeptide stretch be employed in assembly assays, methods and uses as disclosed herein.

All methods, uses and assays described herein are not only useful for scientific purposes but are in particular useful in drug screening methods and for pharmaceutical/pharmacological tests and assays.

As mentioned herein below, it is not only preferred that animal-, tissue- or cell culture systems be employed, but also in vitro test/assay systems are within the scope of the present invention. In vivo and in vitro systems are well known in the art and comprise, inter alia, the production and use of transgenic animals expressing a minimal-tau peptide as defined herein (either mutated or non-mutated), as well as corresponding tissue- and/or cell culture systems. Yet, it is particularly preferred that the minimal tau proteins/peptides as defined herein (either mutated or non-mutated) be employed in in vitro systems which also comprise high-throughput screens.

The peptides/(poly)peptides may be produced recombinantly using a polynucleotide sequence that encodes tau and/or a fragment thereof or may be produced by

biochemical or synthetic techniques. Those methods are known to those of ordinary skill in the art (see, e.g. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989; Merrifield, J. Am. Chem. Soc. 85 (1963), 2149-2146; Stewart, "Solid Phase Peptide Synthesis", WH Freeman Co, San Francisco (1969); Scopes, "Protein Purification", Springer Verlag, New York, Heidelberg, Berlin (1987); Janson, "Protein Purification, Principles, High Resolution Methods and Applications", VCH Publishers, New York, Weinheim, Cambridge (1989); Wrede, "Concepts in Protein Engineering and Design", Walter de Gruyter, Berlin, New York (1994)).

Furthermore, it is envisaged that nucleic acid molecules encoding the minimal tau peptide as defined herein be employed in the method of the present invention. It is, inter alia, envisaged that the minimal tau peptide be expressed in corresponding test systems which comprise animals, preferably transgenic animals, and/or cell or tissue culture systems as described herein below. Preferably, said transgenic animal and/or cell or tissue culture system expresses an amino acid molecule as shown in any one of SEQ ID NOS. 6 to 9.

Additionally, within the scope of the invention are peptides wherein the above mentioned amino acid(s) and/or peptide bonds have been replaced by functional analogs, inter alia by peptidomimetics. Therefore, the present invention also encompasses functional derivatives and/or analogues of said peptides comprising a specific tau-derived peptide which is capable of self-assembly and/or the formation of nucleation sites for PHF-formation. Particularly preferred are peptides comprising specific tau derived peptides which are capable of a β -sheet like interaction. Methods for the preparation of said peptides, (chemical) derivatives and/or analogues are well known to those in the art and comprise, inter alia, recombinant preparation (as described, inter alia, in Biernat (1992), EMBO J. 11, 1593-1597), protein/peptide isolation and purification (as described, inter alia, in Schweers (1995), loc. cit.), or proteolytic methods as described, inter alia, in the appended examples. Further methods for the preparation of peptides/(poly)peptides are described in Sambrook et al., loc. cit., or in Oxender and Fox (1987), "Protein preparation of chemical derivatives and/or analogues are described in, for example,

Beilstein "Handbook of Organic Chemistry", Springer Edition New York, or in "Organic Synthesis", Wiley, New York.

Furthermore, the term "peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs" also relates to a fusion protein/peptide comprising a peptide as defined herein above. Therefore, the "peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs" can comprise (a) further domain(s), said domain(s) being linked by covalent or non-covalent bonds. The linkage can be based on genetic fusion according to the methods known in the art (Sambrook et al., loc. cit.; Ausubel, loc. cit.) or can be performed by, e.g., chemical cross-linking as described in, e.g. WO 94/04686. The additional domain present in the fusion protein/peptide comprising the above mentioned peptide comprising a specific tau derived peptide may be joined directly (i.e. with no intervening amino acids) or may be linked by a flexible linker, advantageously a polypeptide linker, wherein said polypeptide linker comprises plural, hydrophilic, peptide-bonded amino acids of a length sufficient to span the distance between the C-terminal end of said further domain and the N-terminal end of the peptide or vice versa. Said polypeptide linker might be a cleavable linker, e.g. a linker cleavable by specific enzymes.

Said fusion protein/peptide may comprise other functional amino acid sequences, like protein tags (GST, GFP, h-myc-peptide, FLAG, etc.) which are derived from heterologous proteins. These further protein tags may be used, inter alia, in adopted detection systems as described herein in the appended examples.

The term "nucleation sites for PHF assembly" as used in accordance with the present invention means the complex or aggregate formation between at least two peptides comprising a specific tau derived peptide as defined in any one of SEQ IDs 6, 7, 8, 9 or 57 or (a) fragment(s) thereof. The term furthermore comprises short or thin filaments formed in vitro without a paired helical appearance but a high competence to nucleate bona fide PHFs from full length tau and/or fragments thereof. Therefore, the term "nucleation sites for PHF assembly" comprises short dimers (homodimers or heterodimers) of peptides comprising said tau derived peptides or fragments thereof as well as "nuclei" of higher structure which can then elongate into PHFs. The detection of the presence, decrease or absence of such nucleation sites for PHF assembly is well known in the art as described in Friedhoff

(1998a, b) loc. cit. or is illustrated in the appended examples. The detection can be carried out, inter alia, by microscopic and/or spectroscopic methods as explained herein below. Further particular preferred detection methods comprise fluorescence spectroscopy, especially fluorescence spectroscopy employing thioflavine S or T or the detection of the self-fluorescence of tyrosine (like Tyr310 of the human tau sequence, see, inter alia PHF6 or PHF8 as depicted in SEQ ID NOS: 7 and 8, or of PHF43 or K19 fragments as depicted in SEQ ID NO: 6 or 57), as described in the appended examples. Said detection of tyrosine self-fluorescence is particularly preferred when short tau-derived peptides and their aggregation, assembly and/or dimerization is measured.

In accordance with this invention, potential inhibitors, capable of modifying the PHF formation may be (an) antibody(ies). Said antibody(ies) may comprise (a) monoclonal antibody/antibodies, (a) polyclonal antibody(ies) or (a) chimeric antibody(ies). Furthermore, said antibody(ies) comprise(s) synthetic antibodies, antibody fragments, or a chemically modified derivative of any of these.

Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, Nature 259 (1975), 495, and Galfré, Meth. Enzymol. 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals with modifications developed in the art.

As mentioned herein above, the antibodies can be monoclonal antibodies, polyclonal antibodies, chimeric antibodies or synthetic antibodies as well as fragments of antibodies, such as Fab, Fv or scFv fragments etc. Antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. The production of chimeric antibodies is described, for example, in WO 89/09622.

Said antibodies, derivatives and/or fragments thereof may bind to said peptide comprising a specific tau derived peptide as identified herein above and/or to a fragment thereof. Therefore, said antibody(ies), said derivative(s) and/or fragment(s) thereof may act as an inhibitor of PHF-formation. In one instance, said antibody(ies) can bind to said peptide and thereby be able to block the interaction of tau protein

and/or tau-fragments in vitro and/or in vivo. It is particularly preferred that said antibody, fragment or derivative thereof specifically interacts with the amino acid sequence as depicted in SEQ ID NOs: 7, 8 or 9, or with a fragment thereof.

In addition, oligonucleotides and/or aptamers which may specifically bind to the above mentioned peptide(s) and thereby modify and/or inhibit the PHF-formation in vitro and/or in vivo are also envisaged as potential inhibitors to be tested in the method of the present invention. The term "oligonucleotide" as used in accordance with the present invention comprises coding and non-coding sequences, it comprises DNA and RNA and/or comprises also any feasible derivative. The term "oligonucleotide" further comprises peptide nucleic acids (PNAs) containing DNA analogs with amide backbone linkages (Nielson, Science 274 (1991), 1497-1500). Oligonucleotides which may inhibit PHF-formation and which can be identified and/or obtained by the method of the present invention can be, inter alia, easily chemically synthesized using synthesizers which are well known in the art and are commercially available like, e.g., the ABI 394 DNA-RNA Synthesizers.

In accordance with the present invention, the term aptamer means nucleic acid molecules that can bind to target molecules. Aptamers commonly comprise RNA, single stranded DNA, modified RNA or modified DNA molecules. The preparation of aptamers is well known in the art and may involve, inter alia, the use of combinatorial RNA libraries to identify binding sites (Gold, Ann. Rev. Biochem. 64 (1995), 763-797).

Potential other inhibitors to be screened with the method of the present invention include small molecules which bind to, interfere with and/or occupy relevant sites on tau, fragments thereof and/or on peptides which are derived from tau. Furthermore, said inhibitors comprise molecules capable of interfering with amino acid sequences which are derived from the tau protein sequence and comprise the amino acid sequences as depicted in SEQ ID NOs: 6 to 9 or 57. In particular said inhibitors interfere with the potential β -sheet formation stretch of peptides as depicted in SEQ ID NOs: 7, 8 or 9. Such inhibitors comprise also molecules which bind to other parts of the full-length tau sequence but inhibit the correct folding of said tau protein (and/or fragments thereof) and thereby inhibit the formation of correct β -structures

on and/or within the amino acid sequences as depicted in SEQ ID NOs: 7, 8 or 9. Said molecules might be selected prior to employing the method of the present invention, inter alia, by well known ELISA tests, and/or screening methods like spot membrane binding assays. Further screening methods for "pre-screening" are well known in the art and comprise, inter alia, the screening of phage display libraries, as exemplified, inter alia, in the appended examples. Examples of small molecules include, but are not limited to small peptides (as documented in the appended examples) or peptide-like molecules.

The present invention is particularly useful in assaying for potential PHF-formation inhibitors. It is also envisaged that potential inhibitors, as deduced by other methods known in the art, be further analyzed and/or screened. For example, phage display methods may be employed in order to deduce such potential inhibitors. Said phage display allows the identification of proteins/peptides that interact with a molecule of interest. Such phage display kits are known in the art and commercially available, e.g. Display Systems Biotech # 300-110.

In a preferred embodiment, the invention relates to a method, wherein in step (a) said incubation is carried out in the presence of assembly-competent tau proteins and/or assembly-competent tau protein fragments and wherein in step (b) the presence, decrease and/or absence of PHF or tau filaments is detected. Assembly-competent tau protein(s) and/or fragments thereof may be recombinantly produced or purified. Said proteins or fragments thereof may be derived from different species, e.g., human, mouse, rat, cow, rhesus monkey, or may be derived from human variations of the tau protein, like the FTDP-17 mutations as disclosed in Wilhelmsen (1999), PNAS 96, 7120-7121. Assembly-competent tau proteins are, e.g., full length tau proteins as described in the art, inter alia, in Goedert (1988), Proc. Natl. Acad. Sci. USA 85, 4051-4055; Lee (1988), Science 239, 285-288; Crowther (1994), FEBS letters 337, 135-138; Goedert (1997), Neuroscientist 3, 131-141; Goedert, (1989), Neuron 3, 519-526; Himmler, (1989), Mol. Cell. Biol. 9, 1389-1396; Kosik (1989), Neuron 2, 1389-1397; Nelson (1996), J. Neurochem. 67, 1622-1632. Furthermore, assembly-competent tau protein fragments are known in the art and comprise, inter alia, the fragments K11, K12, K18 or K19, as described in

Kampers (1996), FEBS letters 399, 344-349. As documented in the appended examples, such a method is particularly useful in screening and/or verifying potential inhibitors of PHF-formation and/or pathological tau-aggregation.

The method(s) of the present invention may be carried out in a physiological buffer system as described, inter alia, in the appended examples. Within the scope of the present invention are furthermore, buffer systems and experimental set-ups, wherein the method(s) of the present invention are carried out in the presence of anionic co-factors for PHF-formation as described herein below. The anionic co-factors comprise, inter alia, heparin, polyglutamic acid, ribonucleic acid. Furthermore, said physiological buffer system may allow oxidation processes, e.g. oxidation of cysteins (see Schweers (1995), P.N.A.S. 92, 8463-8467).

Additionally, the present invention relates to a method for identifying and obtaining an inhibitor of PHF formation comprising the steps of:

- (a) contacting a peptide comprising a specific tau-derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 and 9 or (a) fragment(s) thereof with the first molecule known to bind to said peptide to form a first complex of said peptide and said first molecule;
- (b) contacting said first complex with a compound to be screened; and
- (c) measuring whether said compound displaces said first molecule from said first complex.

Said "first molecule known to bind to said peptide" may comprise, but is not limited to antibodies, antibody fragments, antibody derivatives, aptamers, specific oligonucleotides and/or small molecules which specifically bind to/interact with said peptide as described herein. Said small molecules may comprise, inter alia, synthetically produced peptide-analogs which may comprise, inter alia D-amino acids.

Said "measuring" in step (c) may be carried out by specific immunological and/or biochemical assays which are well known in the art and which comprise, e.g., homogenous and heterogenous assays as described herein below. A further method which may be employed comprises FRET (fluorescence resonance energy

transfer; as described, inter alia, in Ng, Science 283 (1999), 2085-2089).

In a preferred embodiment, the present invention relates to the above described method wherein said measuring step (c) comprises the measurement of a formation of a second complex of said tau-derived peptide and said compound.

The measurement of a complex formation is well known in the art and comprises, inter alia, heterogeneous and homogeneous assays. Homogeneous assays comprise assays wherein the binding partners remain in solution and comprise assays, like agglutination assays (see herein below). Heterogeneous assays comprise assays like, inter alia, immuno assays, for example, ELISAs, RIAs, IRMAs, FIAs, CLIAs or ECLs.

Further methods for measurement comprise the monitoring of complex and/or aggregate formation in real time by the fluorescence of dyes such as thioflavine S or T (as described in Friedhoff (1998a, b) loc. cit., or as illustrated in the appended examples), or the measurement of self-fluorescence, like the self-fluorescence of tyrosine (as illustrated in the appended examples).

In a more preferred embodiment, the method of the invention is a method wherein said measuring step (c) comprises the measurement of the amount of said first molecule that is not bound to said tau-derived peptide.

Again said measurement may comprise a plurality of measuring and/or detection methods which are well known in the art. For example, said first molecule and therefore said amount may be measured by immuno detection methods or by the detection of a label which was added to said first molecule. Said label may be, inter alia, a tag, a fluorescent marker, an enzyme, a peptide or a radioactive marker.

Such labels are well known to the person skilled in the art and comprise, inter alia, horse radish peroxidase, alkaline phosphatase, β -galactosidase, fluorochromes (like fluorescein, rhodamine, Texas Red, etc.), colloidal metals (like gold particles), biotin, digoxigenin and chemi- or bioluminescent compounds.

Any measuring or detection step of the method(s) of the present invention may be assisted by computer technology. For example, in accordance with the present invention, said detection and/or measuring step can be automated by various means, including image analysis, spectroscopy or flow cytometry.

In a particularly preferred embodiment, said measurement/detection is carried out in a fluorescence assay employing, inter alia, thioflavin S or T (see herein above) or tyrosine self-fluorescence. Such assays are well known in the art, as illustrated in the appended examples and/or as described in Friedhoff (1998a, loc. cit.). Said tyrosine self-fluorescence is partially useful for measurements and/or detections of assembly, aggregation, dimerization processes, or the like, where small peptides/proteins are involved which comprise an intrinsic tyrosine. For example, the presence and/or formation of aggregation products of peptides comprising a specific tau-derived peptide as defined, inter alia, in any one of SEQ ID NOS: 6, 7, 8, 9 or 57 can be readily measured, as demonstrated in the appended examples.

Therefore, the detection/measuring step(s) of the method(s) of the invention can be easily performed according to methods known in the art such as described herein or as demonstrated in the appended examples. In particular, the detection/measuring step(s) of the method(s) of the invention can be carried out by employing antibodies directed against said tau derived peptides. Said antibodies may comprise conformation-dependent antibodies. The use of antibodies is particularly preferred in detection methods like ELISA.

The compounds/inhibitors identified and/or obtained according to the method of the invention, in particular inhibitors interacting with said peptides comprising a specific tau derived peptide as defined herein or (a) fragment(s) thereof, are expected to be very beneficial as neuroprotective agents. The inhibitors identified are thus expected to be very useful in diagnostic and in particular for therapeutic applications.

Thus, in addition, the present invention relates to a method for the preparation of a pharmaceutical composition comprising the steps of a method described herein above and synthesizing and/or formulating the compounds identified, obtained

and/or screened in step (b) or derivative thereof in a pharmaceutically acceptable form. The therapeutically useful inhibitor/compound identified according to the method of the invention may be formulated and administered to a patient as discussed herein below. For uses and therapeutic doses determined to be appropriate by one skilled in the art, see *infra*.

In a more preferred embodiment, the method of the invention relates to a method wherein said peptide comprising a tau-derived peptide is bound to a solid phase.

The method of the invention is preferably carried out in the liquid phase, however, said peptide can be bound to a solid phase/a solid carrier. Additionally, as pointed out herein above, said peptide can be additionally labeled in various ways, *inter alia*, by fluorescence or radio labels. Said solid phase comprises, but is not limited to, a plastic, a glass, a silicon, a colloidal metal, a cellulose and/or a polymeric support. Said solid support is selected from the group consisting of solid organic polymers, cellulose/cellulose-based membranes, colloidal metal particles, plastic surfaces, or any combination thereof. A number of supports known in the art are suitable for serving the purposes of the present invention. Such supports may comprise, *inter alia*, membranes, plates, stripes, wells, beads, microchips or containers. Suitable materials for such supports or materials for further coating of said supports include, but are not limited to, glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, latex, dextran, nylon, amyloses, natural and modified celluloses, like nitrocellulose, polyacrylamide, agaroses, magnetite and metals. The above mentioned colloidal metal particle may be, *inter alia*, a gold particle, and said above mentioned plastic surface comprises the well of a microtiter plate. Additionally, said above mentioned solid organic polymer may be or comprise a latex bead. Combinations of several supports, such as, e.g. latex beads and colloid metal particles, are also within the scope of the present invention.

Said particles bound to solid supports/phases are useful in the method of the present invention when, *inter alia*, said detection and/or measuring step is carried out by homogeneous assays, for example by an agglutination assay which measures the formation of a complex of said peptides. An example of such a homogeneous assay would be a latex enhanced turbimetric assay. In accordance

with the present invention it might be envisaged that either the direct interaction of a peptide comprising a specific tau derived peptide as defined in SEQ ID NOs: 6, 7, 8, 9 and/or 57 with another of said peptides is measured or that at least one of the binding/complex partners is/are bound to the above described solid phases/supports, such as latex beads, and that the interaction/agglutination of said solid support is measured. Such a measurement is known to the person skilled in the art and comprises, inter alia, electric field variation, magnetic field variation, turbidimetric variation and/or light scattering. Said measurement, however, may also involve adapted methods as described herein and in the appended examples, like fluorescence assays employing thioflavin S or T or self-fluorescence of tyrosine.

In a particular preferred embodiment, the method of the present invention comprises a method, wherein the incubation step involving a peptide comprising a specific tau derived peptide as defined herein is carried out in the presence of (poly)anions. Said (poly)anions may comprise, but are not limited to, heparin, nucleic acid molecules, or acidic peptides (like poly-Glu).

In accordance with the present invention, the method of the present invention also comprises the use of in vivo-test systems. It is, inter alia, envisaged that transgenic animals comprise peptides as defined herein, i.e. peptides comprising specific tau derived peptides as defined in any one of SEQ ID NOS: 6, 7, 8, and 9. Said transgenic animal preferably expresses the "minimal tau peptide" as defined herein in the nervous system, however, expression in other organs of said transgenic animal are within the scope of the present invention.

Furthermore, it is envisaged that the minimal tau peptide as defined in the present invention (SEQ ID NOS. 6 to 9) is expressed in tissue and/or cell culture systems.

Said tissue and/or cell culture systems may comprise primary as well as secondary tissue culture systems. For example, cultured hippocampal neurons, cultured neuronal stem cells, cultured (embryonic) dorsal root ganglia or cultured spinal cord, may be employed in the method of the present invention. Cell systems comprise, but are not limited to, neuronal cells like PC12-cells, NT2, N-A or non-neuronal N2A cells, like HEK293, CHO, Hela, NIH3T3.

The above-mentioned tissue and/or cell cultures may for example be transfected with nucleic acid molecules encoding the minimal peptide as defined herein. Transfection systems are well known in the art and comprise but are not limited to CaCl_2 -transfections, transfections employing lipofectamine, viral transfection systems, like adenoviral or lentiviral systems, and the like.

In full length tau isoforms and tau-derived peptides, site-directed mutagenesis of the hexapeptide as shown in SEQ ID NOS 7 or 8 that inhibits its beta-structure forming capacity also inhibits aggregation (for example, replacement of V, Q, I by N, A, E, deletion of VQI, or exchange of single residues by a proline). In cell models and transgenic animal models the use of such mutations in the hexapeptide PHF6 is therefore particularly useful to determine whether tau aggregation per se is toxic (gain of toxic function), or whether other properties of tau play a role in degenerating neurons of Alzheimer's disease (e.g. destabilization of microtubules after loss of tau-microtubule binding, or inhibition of intracellular transport, i.e. loss of function). Furthermore, proteins/peptides comprising (a) mutated and/or modified version(s) of the hexapeptide as defined in SEQ ID NOS 7 or 8 may be particularly useful in drug screening assays and/or may be employed as inhibitors of β -sheet formations.

Furthermore, the present invention relates to an inhibitor identified or obtained by the method described herein. In a preferred embodiment, said inhibitor specifically binds to a peptide comprising a tau-derived peptides as defined in any one of SEQ ID NOS: 6, 7, 8 or 9 or (a) fragment(s) thereof.

The term "specifically binding" as used in accordance with the present invention means "specifically interacting" with. Said interaction may be, inter alia, covalently, non-covalently and/or by hydrophobic interaction. As inhibitors, as identified or obtained by the method for the present invention are envisaged small molecule peptides, antibodies, aptamers and the like. It is particularly preferred that said inhibitor is capable for breaking and/or interfering with the β -structure of the minimal tau-peptide as defined herein or which are capable for breaking and/or interfering with the β -sheet like interaction of tau.

The invention relates in addition to a composition comprising the inhibitor as

identified or obtained by the method as described herein above or the inhibitor which specifically binds to a peptide comprising a tau derived peptide as defined herein above or (a) fragment(s) thereof. In a preferred embodiment, said inhibitor is an antibody, as described herein above. In a particularly preferred embodiment, said antibody is a monoclonal antibody. As mentioned herein above, said inhibitor also comprises small molecule peptides, aptamers and/or compounds capable of interfering with a β -sheet formation.

The term "composition" as used in accordance with the present invention comprises at least one inhibitor as identified or obtained by the method of this invention or at least one inhibitor which specifically binds to a peptide comprising a tau derived peptide as defined herein above and, optionally, further molecules, either alone or in combination, like e.g. molecules which are capable of interfering with the formation of neurofibrillary tangles and/or the formation of amyloid plaques. The composition may be in solid, liquid or gaseous form and may be, inter alia, in a form of (a) powder(s), (a) tablet(s), (a) solution(s) or (an) aerosol(s). In a preferred embodiment, said composition comprises at least two, preferably three, more preferably four, most preferably five inhibitors as defined herein above.

In a preferred embodiment, said composition is a diagnostic or a pharmaceutical composition.

The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, excipient and/or diluent.

Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g. by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. Most preferably, said administration is intra-cerebral and/or by an administrative route which by-passes the blood/brain

barrier. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, general health, age, sex, the particular compound to be administered, time and route of administration, and other drugs being administered concurrently. Pharmaceutically active matter may be present, inter alia, in amounts between 1 ng and 100 mg per dose; however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors.

The compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously. The compositions of the invention may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site (like the brain) or by catheter to a site in a (brain) artery. Furthermore, the pharmaceutical composition of the invention may comprise further agents, depending on the intended use of the pharmaceutical composition. Such agents may be drugs acting on the central nervous system, like neuroprotective factors, cholinesterase inhibitors, agonists of M1 muscarinic acetylcholine receptor, drugs leading to increased synthesis of acetylcholine, as well as non-steroid antiinflammatory drugs (NSAIDs), hormones, antioxidants, inhibitors of the production and/or aggregation of A β , or inhibitors of the production, aggregation and/or phosphorylation of tau. Further drugs/agents which may be comprised in the pharmaceutical composition of this invention comprise any Alzheimer-relevant medication as, e.g., described under www.alzforum.org/members/research.

In a preferred embodiment of the invention, the composition of the present invention is a diagnostic composition further comprising, optionally, suitable means for detection. The diagnostic composition comprises at least one of the aforementioned inhibitors of the invention.

The pharmaceutical compositions, as well as the methods of the invention described supra or the uses of the invention described infra can be used for the treatment of all kinds of diseases hitherto unknown or being related to or dependent on pathological tau aggregation. They may be particularly useful for the treatment of

Alzheimer's disease and other diseases where intracellular deposits of tau, like frontotemporal dementia, FTDP-17-mutations (Wilhelmsen (1999), loc. cit) and other tauopathies, appear to play a role. They may be desirably employed in humans, although animal treatment is also encompassed by the methods, uses and compositions described herein.

In yet another embodiment, the present invention relates to a method for detecting and/or measuring PHF formation comprising the steps of:

- (a) incubating a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 or 9 or fragments thereof, with tau-proteins and/or fragments thereof under conditions which permit assembly of tau-proteins and/or fragments thereof into PHFs; and
- (b) detecting the presence, absence, decrease or increase of PHFs and/or nucleation sites of PHF assembly.

The incubation(s) of step (a) in the method(s) of the present invention may be carried out in vitro solely in the presence of tau-proteins and/or fragments thereof. However, further co-factors which might promote PHF assembly/formation and/or formation of nucleation sites for PHF assembly may be added. Such co-factors are well known in the art and comprise, e.g., anionic co-factors, like polyglutamate, RNA or heparin (see, inter alia, Friedhoff (1998a), loc. cit.). The detection/measuring step (b) may be carried out as described herein and in the appended examples and may comprise microscopic and/or spectroscopic methods.

In a more preferred embodiment, the detection and/or measuring step in the method of the present invention is carried out by microscopic or spectroscopic means. In a yet more preferred embodiment said microscopic means comprises electron microscopy and said spectroscopic means comprises circular dichroism spectroscopy, fluorescence spectroscopy or infrared spectroscopy (FTIR). In a particular preferred embodiment said fluorescence spectroscopy comprises a thioflavine S or T assay or a tyrosine self-fluorescence-assay, as described herein. For example, in said tyrosine self-fluorescence assay, the change in fluorescence of Tyr 310 (within the β -structure forming hexapeptide of the present invention) of tau

changes (see, inter alia, appended examples VI). Said microscopic and/or spectroscopic means are well known in the art as illustrated, inter alia, in the appended examples. Further detection methods are described in the art and comprise methods as described in the appended examples. As mentioned herein above, suitable methods comprise not only microscopic and/or spectroscopic means but comprise also heterogeneous or homogeneous assays, like ELISAs or agglutination assays.

In yet another embodiment, the present invention relates to a kit comprising at least one of the following:

- (a) a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 and 9 or (a) fragment(s) thereof, and/or a nucleic acid molecule encoding said peptide or (a) fragment(s) thereof;
- (b) tau-protein(s) and/or fragments thereof as defined herein above;
- (c) a solid support as defined herein above,

adopted for carrying out the method of the invention, optionally further comprising a standard and/or suitable means for detection.

Furthermore, the present invention relates, in another embodiment, to a kit comprising an inhibitor or a composition as defined herein above. Such (a) kit(s) of the present invention may comprise a carrier means being compartmentalized to receive in close confinement one or more container means such as vials, tubes and the like, each of the container means comprising one of the separate elements to be used in the method of the invention or for the composition of the invention. For example, one of the container means may comprise the peptide comprising a tau-derived peptide as defined herein, soluble or bound to a carrier. A second container may comprise soluble tau protein(s) or (a) fragment(s) thereof, in lyophilized form or in solution. In addition, the carrier means may also contain a plurality of containers each of which comprises different, predetermined amounts of peptides as defined herein above. These latter containers can then be used to prepare a standard curve into which can be interpolated the results obtained from the methods of the invention identifying and obtaining an inhibitor capable of modifying PHF formation in vitro and/or in vivo.

The kit(s) of the invention is (are) particularly useful in carrying out the method of the invention that has been described in detail herein above. In a further embodiment, the present invention relates to the use of a peptide comprising a specific tau derived peptide as defined herein above for carrying out the method(s) of the invention for identifying and obtaining an inhibitor, capable of modifying the PHF formation in vitro and/or in vivo, for the preparation of a pharmaceutical composition and/or for detecting and/or measuring PHF formation in vitro.

A particularly preferred embodiment of the invention relates to the use of the kit(s) of the invention for carrying out the methods of the invention.

Furthermore, the present invention relates to the use of a peptide comprising a specific tau derived peptide as defined in SEQ ID Nos: 6 to 9 and/or a nucleic acid molecule encoding said peptide for carrying out the method of the present invention and/or for screening and/or for the identification of an inhibitor, capable of modifying PHF formation. These screening and/or identification methods comprise not only methods wherein amino acid sequences, as depicted, inter alia, in SEQ ID NOs: 6 to 9, are used but also relate to methods wherein nucleic acid molecules encoding these peptides are employed. Proteins and other compounds which bind to the peptides comprising tau derived peptides as described in the present invention are candidates or inhibitors of PHF formation according to the present invention. Such binding compounds can be "captured" using the yeast two-hybrid system (Fields and Song (1989), Nature 340, 245-246).

Therefore, and in context of the method and use as described herein, it is also envisaged that nucleic acid molecules encoding the minimal tau peptide as defined herein, may be employed in order to carry out the methods of the present invention or may be employed in the use of the present invention.

A modified version of the yeast two-hybrid system has been described by Roger Brent and his colleagues (Gyuris, J. et al. (1993), Cell 75, 791-803; Zervos, A.S. (1993), Cell 72, 223-232). Preferably, the yeast two-hybrid system is used according to the present invention to capture compounds which bind to the peptides as identified in SEQ ID Nos: 6 to 9. Such compounds are good candidate inhibitors of PHF formation of the present invention. Other screening and/or identification

methods are well known in the art and comprise, inter alia, phage display (as described, inter alia in US 5,541,109) or affinity-labelings via cross-linkers. Furthermore, the method of the present invention is therefore also useful in and can easily be adapted to high-throughput screenings and/or computerized screening assays.

The present invention relates in another embodiment to a non-human transgenic animal expressing the minimal tau peptide as defined hereinabove. Most preferably, said transgenic animal comprises and/or expresses the minimal tau peptide as defined in SEQ ID NOS. 6 to 9 or a functional homologue thereof. Said transgenic animal may, inter alia, be selected from the group consisting of mouse, rat and sheep.

Yet, it is also envisaged that said transgenic animal comprises and/or expresses a minimal tau peptide and/or tau peptide and/or (a) fragment(s) of tau which comprise a hexapeptide as defined in SEQ ID NOS 7 or 8, wherein at least one amino acid with intrinsic β -sheet propensities (like, inter alia, V, Q, I) has been replaced with (an) amino acid(s) which do not comprise such intrinsic β -sheet propensities or comprise limited intrinsic β -sheet propensities (like, inter alia, N, E, A, P).

Accordingly, the present invention also relates to the uses and methods as disclosed herein, wherein the peptide comprising a specific tau-derived peptide as defined in any one of SEQ ID NOS 6 to 9 further comprises in the hexapeptide as defined in SEQ ID NOS 7 or 8 (and which are comprised in SEQ ID NOS 6 or 9) at least one, at least two, at least three or at least four mutations and/or modifications. Said mutation and/or modification may comprise exchanges, substitutions, additions and/or deletions. It is particularly preferred that, depending on the described uses and methods, said mutations and/or modifications comprise the replacement of amino acids with high intrinsic β -sheet propensity(ies) with amino acids with similarly high intrinsic β -sheet propensity(ies) (e.g., replacement of V, Q and/or I, with, e.g. T, F and/or Y) or the replacement with amino acids with lower or no intrinsic β -sheet propensity(ies) (e.g., replacement of V, Q and/or I with N, A and/or E or the exchange of at least one residue by proline). Therefore, the present invention also relates to uses and methods as disclosed herein wherein the above mentioned mutation and/or modification comprises the replacement of at least one

amino acid in the hexapeptide as depicted in SEQ ID NOS. 7 or 8 (or in proteins/peptides comprising said hexapeptide).

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step.

The figures show:

Fig. 1 Bar diagram of tau constructs and peptides. (a) htau40, the longest isoform in the human CNS, containing four repeats of ~31 residues (labeled 1-4) and two inserts near the N-terminus. Residue numbering follows that of htau40 throughout. (b) htau23, the smallest and fetal isoform, lacking the N-terminal inserts and repeat R2. (c) K19 represents only the repeat domain of htau23, i.e. R1, R3, R4 (i.e. 94 residues, Q244-N368, but without V275-S305). (d) PHF43, a subfragment of K19, containing the end of R1, all of R3, and the beginning of R4, but without R2 (43 residues). (e) PHF8, 8 residues spanning the junction between R1 and R3. (f) PHF6, 6 residues from the beginning of R3. The other peptides (V318-K321, V318-G335 and G335-E342) span the PHF43 sequence and were used for analysis by CD.

Fig. 2: Kinetics of PHF assembly. The assembly of tau or tau fragments was measured fluorimetrically, using the fluorescence of ThS (Friedhoff et al., 1998a). Protein concentrations were 20 μ M, in the presence of 5 μ M heparin and 20 mM NH_4Ac , at room temperature. PHF43 assembles rapidly and spontaneously (diamonds, top curve, $t_{1/2}$ = 0.75 min), but htau23 is very slow by comparison (circles, bottom curve, $t_{1/2}$ = 180 min). K19 shows intermediate kinetics (triangles, $t_{1/2}$ = 12 min). Htau23 can be speeded up to a similar rate as K19 in the presence of seeds from sonicated fibers obtained after PHF43 assembly (squares, $t_{1/2}$ = 14 min). The K19 mutants ($\text{K19}^{\Delta\text{VQI}}$, K19^{NAE} and $\text{K19}^{\text{Y310E}}$) showed no aggregation even after several hours (filled triangle at bottom right).

Fig. 3: Peptides derived from tau and their ability for PHF assembly.

The peptide K19 contains the repeats 1, 3, and 4 of tau, but repeat 2 (exon 10) is absent, as in the fetal human isoform tau23 (see Fig. 1). In the standard numbering according to htau40, the longest isoform in the human CNS, K19 extends from residue 244 to 368, but lacking the 31 residues 275-305 (which in 4-repeat isoforms would be inserted after K275, labeled with an asterisk). Each repeat terminates with a characteristic PGGGX motif. Mutations of K19 (K19^{ΔVQI}, K19^{NAE} and K19^{Y310E}) are indicated below the K19 sequence. Chymotrypsin cleaves K19 after Y310 and F345 and thus cuts the minimal interaction motif in two parts. GluC at pH 4.0 cleaves K19 after E264, E337 and E342, leading to four fragments as defined in SEQ ID NOS: 52, 6, 53 and 54. This generates the 43 residue peptide PHF43 (underlined, N265-E337 without the second repeat; see also SEQ ID NO:6). GluC at pH 7.8 cleaves K19 after D252, E264, D314, and E337, leading to five fragments as depicted also in SEQ ID NOS:55 to 59. It cleaves PHF43 into two halves but leaves the minimal interaction motif intact (see also SEQ ID NO:57). Other synthetic peptides are listed below: PHF6 (SEQ ID NO: 8), PHF8 (SEQ ID NO: 9), V313-K321 (SEQ ID NO: 17), V318-G335 (SEQ ID NO: 18), G335-E342 (SEQ ID NO: 19). As demonstrated in the appended examples, fragments comprising the minimal VQIVYK motif (SEQ ID NO:8) are capable of specific aggregation (asterisk) and/or the formation of nucleation sides for PHF formation (+).

Fig. 4: Electron micrographs of fibers obtained from the self-assembly of tau or tau peptides. Assembly conditions were the same as in Fig. 2 (20 μM protein, 5 μM heparin), except E and F (660 μM peptide, 660 μM heparin). A-C show mostly twisted filaments (width ~10-20 nm) resembling Alzheimer PHFs polymerized from (A) htau23, (B) htau23 plus seeds made from PHF43, (C) PHF43. (D) shows the seeds obtained by sonication of PHF43 fibers. (E) and (F) show filamentous aggregates with variable diameters obtained from the short peptides PHF8 and PHF6.

Fig. 5: Peptide spot membrane interactions between PHF43 and peptides derived from the repeat region of tau.

The region of tau from L253 in repeat 1 to D348 in repeat 4 (encompassing the sequence of PHF43) was subdivided into consecutive 15-mer peptides staggered by 3 residues, synthesized and covalently attached to a cellulose membrane (Frank, J. Biotechnol. 41 (1995), 259-272), and incubated with iodinated PHF43. The bars represent the bound radioactivity determined by autoradiography. The strongest interaction occurs around spot 4-25 which contains the sequence of PHF6 (VQIVYK, bold) at the beginning of R3. Another cluster of strong interaction occurs around spot 4-16 which harbors the analogous sequence in R2 (VQIINK, bold).

Fig. 6: CD spectroscopy of tau constructs and tau polymers. CD spectra were obtained at 50 μ M protein concentrations in 10 mM NH_4 -acetate at room temperature, in the absence or presence of 50 μ M heparin and/or 50% TFE.

(a) htau23 monomers (circles), dimers (triangles), and assembled PHFs (solid line) show similar CD curves with or without heparin (filled or open symbols). The minimum is around 200 nm, indicating that a random coil structure predominates independently of dimerization or polymerization.

(b) K19 monomers (SEQ ID NO: 10; without heparin open circles, with heparin filled circles) and dimers (without heparin open triangles, with heparin filled triangles) show similar CD curves, with a mostly random coil structure (minimum around 200 nm), except after polymerization with heparin (solid line) which indicates an increase in beta sheet structure.

(c) PHF43 monomers (SEQ ID NO: 6; without heparin open circles, with heparin filled circles) and dimers without heparin (open triangles) show mostly random coil structure, but a noticeable shift to beta sheet structure when dimers are assembled into PHFs in the presence of heparin (solid line).

(d) PHF8 (SEQ ID NO: 9; without heparin open circles, with heparin filled circles) and PHF6 (SEQ ID NO: 8; without heparin open triangles, with heparin filled triangles) show mostly random coil structure, but shift to more beta sheet structure (especially PHF6) upon polymerization in the presence of heparin (compare Fig. 2).

(e) Three peptides (V_{313} DLSKVTSK $_{321}$, SEQ ID NO: 17; without heparin open circles, with heparin filled circles, V_{318} TSKCGSLGNIHHKPGGG $_{335}$ SEQ ID NO: 18

without heparin open triangles, with heparin filled triangles, G₃₃₅QVEVKSE₃₄₂, SEQ ID NO: 19; without heparin open squares, with heparin filled squares) derived from PHF43 (but not including the sequence of PHF8) show mostly random coil structure, little dependence on heparin, and no polymerization.

(f) K19 (open circles) and PHF43 dimers (open triangles) and PHFs (K19, filled circles, PHF43, filled triangles) in the presence of 50% TFE. This tends to induce alpha-helical conformation, most visible in K19 dimer but less in K19-PHFs which are restricted in their conformation. A similar change is observed with PHF43.

Fig. 7: Secondary structure content of tau derived peptides. Secondary structure components of tau constructs and peptides in monomeric, dimeric, and polymeric states, without or with 50% TFE. The secondary structure assignment was calculated from the CD spectra according to Greenfield and Fasman (Greenfield and Fasman, Biochemistry 8 (1969), 4108-4116).

Fig. 8: Excitation spectra of tyrosine fluorescence of peptides derived from tau protein. (a) K19, (b) PHF43, (c) PHF8, (d) PHF6. All peptides contain Tyr310 as the only tyrosine. The fluorescence emission is observed at 310 nm, the excitation wavelength is scanned between 250 and 300 nm. Solid lines represent soluble peptides without heparin, dashed lines show peptides after aggregation in the presence of heparin. Note that aggregation causes a shift of the excitation maximum by about 5nm.

Fig. 9: Screening for inhibitory peptides. The peptides were preincubated for 30 minutes at room temperature with K19 (final concentration 50 μ M) which PHF aggregation was induced with PHF43 at concentrations of 50, 100 and 200 μ M in a 384 well plate and measured by ThS-assay. The inhibitory peptides G10 and F6 were found as interaction partners for the hexapeptide SEQ ID NO: 7 with a phage display approach described above. As a control two samples of K19 without peptides are also shown. Note that the inhibitory peptide G10 at a concentration of 200 μ M shows a more than 50 % inhibition of PHF aggregation and the peptide F6 shows a 30 % inhibition at 100 μ M.

The invention will now be described by reference to the following biological examples which are merely illustrative and are not to be construed as a limitation of scope of the present invention.

EXAMPLE I

Proteolytic degradation products of the repeat domain cause efficient assembly of PHFs

Earlier efforts to reconstitute PHFs in vitro had shown that tau constructs containing roughly the repeat domain polymerized much more readily than the full-length protein (Wille, loc. cit.), consistent with the observation that the repeat domain forms the core of PHFs from Alzheimer brains (Wischik, loc. cit.). To achieve PHF assembly from intact tau it was necessary to add polyanionic cofactors such as heparin, RNA, or poly-Glu (Goedert, loc. cit.; Kampers, loc. cit.; Perez, loc. cit.). However, it was noted that different preparations of tau protein showed a considerable variability in their assembly efficiency, and that some of the more readily aggregating preparations contained proteolytic breakdown products, as judged by SDS gels. Tau constructs were digested with different proteases, the breakdown products were characterized and they were analyzed for their assembly behaviour. In this study, assembly behaviours were studied as follows: varying concentrations of tau isoforms or tau constructs and fragments (typically in the range of 1-100 μ M) in volumes of 20-500 μ l were incubated at 37°C in 50 mM NH_4Ac , pH 7.0 or 20 mM MOPS-NaOH, pH 7.0 containing anionic cofactors (polyglutamate, RNA or heparin) as described (Friedhoff, loc. cit.). Incubation times varied between minutes up to several days. PHF formation was always confirmed by electron microscopy. Here, construct K19, a derivative of the fetal tau isoform (htau23) was employed for assembly studies. K19 contains only three repeats (R1, R3, R4; the second repeat R2 is absent due to alternative splicing; Fig. 1). Construct K19 (SEQ ID NO: 10) was expressed, like human tau 23, in E.coli as described (Biernat et al, EMBO J. 11 (1992), 1593-1597). The proteins were expressed and purified as described in the art, employing heat stability and FPLC Mono S (Pharmacia) chromatography, as described, inter alia, in Gustke (1994),

Biochemistry 33, 9511-9522. The purity of proteins was verified by SDS-PAGE. Protein concentrations were determined by Bradford assay. Synthetic peptides were obtained from Eurogentec SA (Seraing, Belgium). Construct K19 was digested with chymotrypsin, trypsin, AspN, and GluC. Briefly, different fragments of K19 were generated by proteolysis with the above mentioned proteases. Extensive proteolysis by trypsin (ratio w/w 1:100, in 50 mM NH_4CO_3 pH 8.4, 37°C for 2 h), limited proteolysis by chymotrypsin (ratio w/w 1:200, in 50 mM NH_4CO_3 pH 8.4, RT, for 30 min) and extensive proteolysis by GluC (w/w 1:100, in 50 mM NH_4Ac pH 4.0 or 50 mM NaHPO_4 pH 7.8, RT, overnight). The specificity of GluC depends on the buffer and pH: in ammonium acetate pH 4.0 only peptide bonds C-terminal of Glu are cleaved (leading to fragments as shown in SEQ ID NOS: 52, 6, 53 and 54), in phosphate buffer pH 7.8 peptide bonds C-terminal of Asp and Glu are cleaved; leading to fragments as shown in SEQ ID NOS: 55 to 59).

Obtained peptides were purified by reverse phase HPLC on a C18 reverse phase column (Vydac) on a SMART HPLC system (Pharmacia) with a standard gradient from 0-50 % buffer B (80% acetonitrile v/v in 10 mM NH_4Ac pH 7.0, buffer A 10 mM NH_4Ac pH 7.0) in 8 ml and 50-100% B in 2 ml. The peptide PHF43 was purified by gel filtration on a Peptide-Gelfiltration (Pharmacia) with 100 mM NH_4Ac pH 7.0 at a flow rate of 40 $\mu\text{l}/\text{min}$. Peptides were lyophilized after HPLC and analyzed by MALDI mass spectrometry (Maldi II, Shimadzu) and N-terminal sequencing (ABI-476). Peptide concentrations were determined by fluorescamine assay (Udenfriend, Science 178 (1972), 871-872).

One of the proteolytic products was a fragment, generated by GluC digestion and termed PHF43 (SEQ ID NO: 6), comprising only 43 residues, essentially the third repeat plus flanking stretches on either site (tau sequence 265-338 without the second repeat, 275-305; the numbering of the amino acids is that of the isoform htau 40 containing 441 residues described in Goedert (1989), EMBO J. 8, 393-399; Figs. 2 and 3). This fragment assembled much more rapidly than other fragments or intact tau, as judged by electron microscopy and the ThS fluorescence assay (half time 0.75 min, compared with 12 min for K19 and 180 min for htau23, Fig. 2). For electron microscopy studies, protein solutions were diluted to 1-10 μM and were

placed on 600-mesh carbon-coated copper grids for 1 min and negatively stained with 2% uranyl acetate for 45 sec. The specimen were examined in a Philips CM12 electron microscope at 100 kV. The Thioflavin S-assay was carried out as previously described (Friedhoff et al, loc. cit.). Fluorescence was measured with a Fluoroskan Ascent (Labsystems) with an excitation filter of 480 ± 5 nm and an emission filter of $510 \text{ nm} \pm 5 \text{ nm}$ in a 384 well plate. Measurements were carried out at room temperature in ammonium acetate 50 mM, pH 7.0 or 20 mM Na-MOPS pH 7.0 with 5 μ M ThS unless otherwise stated. Background fluorescence and light scattering of the sample without thioflavine was subtracted when needed.

As with other tau constructs, efficient assembly required the presence of polyanions (e.g. heparin, RNA, or poly-Glu), as well as initial dimerization by oxidation of Cys322 into disulfide bridges, indicating that dimers form the effective building blocks of assembly (Friedhoff, loc. cit.; Schweers, loc. cit.). In fact PHF43 showed an unusually strong tendency to dimerize (in the absence of DTT) so that more than half was already dimerized upon digestion of K19, and after elution from the reverse phase column the dimer fraction was close to 100%. The reaction was based on the crosslinking of Cys322, the only sulfhydryl group in K19 or PHF43, and could be reversed by reducing agents (e.g. DTT).

EXAMPLE II

PHF43 alone forms straight filaments but rapidly nucleates bona fide PHFs from tau23

Electron microscopy was carried out as described herein above. It could be shown that most fibers obtained after self-assembly of the peptide PHF43 (see Example I) appeared as straight thin filaments, often aggregated laterally, and lacking the periodic ~ 80 nm supertwist that is characteristic of Alzheimer PHFs, which is in contrast to fibers assembled from construct K19 or tau23. Since PHF assembly follows a nucleation-condensation mechanism (Friedhoff, Proc. Natl. Acad. Sci. USA (1998b), 15712-15717), fragments of PHF43 fibers were prepared by sonication (sonicator: Branson scientific; 2 min; output level 5; duty cycle 50%; as described in

Friedhoff (1998b), loc.cit.) and it was asked whether these could function as seeds for PHF assembly from larger tau constructs or full-length htau23. Surprisingly, the seeds made from the fragmented PHF43 filaments were capable of rapidly nucleating bona fide PHFs from K19 or htau23, displaying the typical 80 nm twist (Fig. 2, 4). This means that the interaction between PHF43 molecules must be very similar to that of PHFs, both in a kinetic sense (requiring dimerization and polyanions) and in a structural sense (nucleation of twisted fibers). The smaller diameter of PHF43-fibers could be accounted for by the small size of the peptide, compared to the larger tau constructs and isoforms studied previously (Kampers, loc. cit.; Wille, loc. cit.).

Therefore, PHF43, representing the third repeat plus short flanking sequences of tau assembles within seconds into thin fibers under the same conditions as full-length tau (favored by dimerization and anionic cofactors such as heparin, Fig. 2). Seeds derived by sonication from such fibers are capable of greatly accelerating the assembly of full-length tau into bona fide PHFs, showing that the PHF43 interactions are equivalent to the interactions in PHFs (Fig. 4). Interestingly, K19 mutants, which comprise modifications located within the hexapeptide PHF6 (see herein below), showed no aggregation even after several hours (filled triangle at the bottom right of Fig. 2). These K19 mutations are: K19^{ΔVQI}, K19^{NAE} and K19^{V310E} as indicated in Fig. 3 (see also SEQ ID Nos: 12 to 14).

EXAMPLE III

The hexapeptide PHF6 (306-VQIVYK-311, SEQ ID NO: 8) represents a minimal interaction motif with a predicted beta conformation

In order to test whether the tau-tau interaction can be traced down to an even smaller motif a membrane containing spots of immobilized 15-mer peptides, covering the sequence of the repeats with overlaps of 3 residues between successive peptides (Frank, loc. cit.) was used. This spot membrane binding assay was carried out as follows: Iodo-beads (Pierce) were preincubated with Na¹²⁵I (0.5 mCi in 100 mM Tris pH 7.0) for 5 minutes at room temperature. The purified peptide

PHF43 (50 μ g) was iodinated at Y310 for 5 minutes at room temperature. The reaction was stopped by removing the solution and the mixture was applied to a 1 ml C18 cartridge (Waters), equilibrated with 0.1% TFA. The unbound radioactivity was washed out with 4 ml TFA (0.1%). The radioactive peptide was eluted from the column with 66% acetonitrile, 0.1% TFA. All fractions were analyzed by scintillation counting. The eluate of the labeled peptide was lyophilized and diluted in ammonium acetate 50 mM. The membrane containing the library of overlapping peptides was synthesized according to Frank (1995; loc. cit.). Before use, the membrane was incubated in 100% ethanol, then washed three times with tris buffered saline (5 min, room temperature). The labeled peptide solution was diluted 10-fold in TBS (final concentration 0.1 mg/ml). The membrane was incubated in the peptide solution for 2 hours at room temperature; then washed three times with TBS. Autoradiography on Kodak X-omat film was done overnight.

The peptide spot membrane was probed against the PHF43 peptide, radioactively labeled by iodination with 125 I at Tyr310. The most prominent interaction between PHF43 and the spot membrane was found at peptides surrounding Tyr310 (Fig. 5). This means that the region around residue 310 tends to dimerize. A motif overlapping with the interacting peptides was the hexapeptide $^{306}\text{VQIVYK}^{311}$ (termed PHF6, bold in Fig. 5, SEQ ID NO: 8), at the beginning of R3. A second maximum of interaction was centered around Ile278, covering the sequence $^{275}\text{VQIINK}^{280}$ (SEQ ID NO: 7). This sequence is the equivalent of PHF6 at the beginning of R2 (present only in 4-repeat tau and included in the spot membrane). Remarkably, PHF6 in R3 and its counterpart in R2 represent the only regions in tau where a beta conformation is strongly predicted, consistent with the local clustering of residues with high β -sheet propensity such as V, I, Q, and Y. The PHF-forming interaction between tau or tau-derived peptides is strongly dominated by the hexapeptide $^{306}\text{VQIVYK}^{311}$ (PHF6), derived from the third repeat R3, or the equivalent sequence $^{275}\text{VQIINK}^{280}$ (now termed PHF6*) from the second repeat R2 (Fig. 5).

EXAMPLE IV

CD spectroscopy of tau fragments suggests a β -structure in PHF assembly conditions

The conformation of proteins can be probed by circular dichroism, infrared spectroscopy, or solution X-ray scattering. Earlier studies (Schweers (1995), loc.cit.; Wille (1992), loc.cit.) of tau isoforms had shown that the ordered secondary structure of tau (α -helix or β -sheet) was minimal, below the reliable detection limit of the methods (~5-10%). This had given rise to the notion that tau was a largely random structure, without a well-defined folding pattern, reminiscent of a Gaussian polymer (Schweers (1994), loc. cit.). This view did however not exclude the possibility of a locally ordered structure which should become more visible with shorter tau-derived peptides. Therefore, the CD spectra of tau and its fragments in several conditions (Fig. 6 a-f and Fig. 7) were studied. All measurements were made with a Jasco J-710 CD-Dichrograph (Jasco, Japan) in a cuvette with 0.05 cm path length. For each experiment, 10 spectra were summed up and the molar ellipticity was determined after normalizing for the protein concentrations. The secondary structure interpretation of the CD-data was performed according to Chou and Fasman (Annu. Rev. Biochem. 47 (1978), 251-276), as implemented in the program Dicroprot (Deleage and Geourjon, Comput Appl Biosci, 9 (1993), 197-9).

The above mentioned conditions for CD spectra experiments of tau and its fragments and/or corresponding constructs were as follows:

- (a) The monomeric state: This is obtained in the presence of DTT (1mM) because this keeps Cys322 reduced and prevents dimer formation.
- (b) The dimeric state is obtained by allowing air oxidation of Cys322; this results in almost complete conversion from monomers to dimers (see Schweers, loc. cit.). Dimers of tau isoforms or tau constructs were allowed to form by incubation at 10 mg /ml after removal of DTT. The dimers were separated from monomers by gel filtration on a SuperdexTM 75 column (Pharmacia) equilibrated with 200 mM NH₄Ac, pH 7.0. Fractions were collected and assayed for dimeric K19 by 15 % SDS-PAGE under non-reducing conditions.

- (c) Monomers with added polyanions, e.g. heparin: This could reveal a conformational change induced by heparin independently of aggregation since PHF assembly is normally inefficient in the absence of dimers. Heparin (average MW of 6000) was obtained from Sigma. For CD experiments as described herein, only heparin was usable as cofactor for assembly because poly-Glu interferes with the CD signal of tau and RNA has a strong absorption in the UV range.
- (d) Dimers with added polyanions: This conditions causes the aggregation of tau into PHFs. Concomitant conformation changes can be observed by comparing the initial solution and the final aggregated state.
- (e) Monomers, dimers, or aggregates in the presence of TFE (trifluoroethanol; see Fig. 5), a strong inducer of alpha-helical conformation: This should convert those fractions of the protein that are free to change their conformation into α -helix.

CD spectra are often interpreted in terms of a few idealized structures and their reference spectra (alpha-helix, beta-sheet, random coil, turns). The method yields approximate secondary structure fractions for well-folded proteins but has wide error margins in the case of "natively unfolded" proteins such as tau and interacting cofactors. The spectra were formally interpreted following the method of Chou & Fasman (loc. cit.) and expressed as percentage of alpha, beta, and random coil (Fig. 7). More significant are however the general shapes of the spectra which reveal gross conformational changes. All curves obtained for htau23 have negative molar ellipticities at wavelengths between 190 and 200 nm and show a minimum around 200 nm. This is characteristic of mostly random coil structures and confirms our earlier observations (Schweers (1994), loc. cit.). Neither dimerization nor heparin changes the spectra substantially, arguing that the random coil structure dominates in all cases, even after PHF assembly (solid curve in Fig. 6a). Even if a local beta-structure were formed during PHF assembly, this does not become noticeable with full-length tau. The situation changes as the tau constructs become smaller (Fig. 6b): K19 also displays a mostly random coil structure in the monomeric or dimeric state, even with heparin, but polymerization induces a noticeable change in the spectra so that the minimum becomes wider and is shifted towards higher

wavelengths, indicating a substantial change from random coil to beta structure. This behavior is reiterated in the case of PHF43 (Fig. 6c), showing mostly random coil structures, except after PHF assembly where the content of beta-structure is increased. Fig. 6d compares the curves of PHF6 (VQIVYK) before and after assembly through addition of heparin, as well as PHF8 (= PHF6 plus the preceding two residues, GKVQIVYK, SEQ ID NO: 9); again there is a substantial change from random coil to beta structure after assembly. Note that in the latter two cases the intermolecular interaction is not preceded by disulfide oxidation since Cys322 is not present. Next several peptides derived from the repeat domain of tau were probed. The nonapeptide ³¹³VDLSKVTSK³²¹ (SEQ ID NO: 14) from R3 following after PHF6 does not polymerize and shows mostly random coil with some beta-structure in the presence or absence of heparin. The same is true for the 18-mer peptide ³¹⁸VTSKCGSLGNIHHKPGGG³³⁵ (SEQ ID NO: 15) which represents the second half of R3 that is more conserved between the repeats (sometimes termed the "repeat" in the strict sense, peptide provided by R. Hoffmann and L. Otvos, see Hoffmann, J. Pept. Res. 50 (1997), 132-142). Note that this peptide does not assemble even though it contains Cys322, indicating that the vicinity of Cys alone is not sufficient for PHF formation. Finally, the peptide ³³⁵GQVEVKSE³⁴² (SEQ ID NO: 16) shows a similar behavior, i.e. mostly random coil with some beta-structure, with or without heparin, and no assembly. This peptide is located at the beginning of R4, analogously to PHF8, but evidently does not have the capacity to interact with itself, presumably because it contains sheet-breaking residues. (Note that for the non-assembling peptides the assignment of beta-structure cannot be taken literally since no beta-sheets are formed. The numbers are merely generated by the computer algorithm whose theoretical assumptions are only partly fulfilled here).

In a further set of experiments the influence of the helix inducer TFE (50%) on the CD spectra was tested. The rationale was that monomeric or dimeric molecules should show a substantial conversion to helical structure, whereas polymerized fibers should be less convertible because part of their sequence was locked in the PHF-forming conformation. This expectation was broadly supported by the data (Fig. 6f): In all cases tested, TFE induced a strong shift towards a more helical spectra, as seen by the positive molar ellipticities below 200 nm and the broad

minimum between 210 and 230 nm. The calculated fraction of alpha-helix was larger for the unpolymerized state than after polymerization, as expected (see Fig. 7). The convertible fraction was increased with the size of the protein (i.e. smallest for PHF43, largest for htau23 consistent with the assumption that only a minor fraction of the protein was locked in the PHF interactions. (Note however that the curves give only a qualitative picture of the conformation but do not allow quantitation of the protein domains actually involved in the intra-filament backbone).

In summary, PHF assembly is accompanied by a substantial increase in β -sheet formation (Fig. 6).

This is not observed upon dimerization or addition of anionic cofactors alone, indicating that beta-sheet formation is an essential part of PHF assembly. (5) The hexapeptides ³⁰⁶VQIVYK³¹¹ in R3 and its counterpart ²⁷⁵VQIINK²⁸⁰ in R2 are the only two spots in the tau sequence where a beta-conformation is strongly predicted. This prediction is based on a comparison of all known sequences of the tau/MAP2/MAP4 family of proteins, searching for a signature motif of this class of MAPs and the corresponding secondary structure (Fig. 7). The pronounced tendency for beta-structure is explained by the local clustering of strong beta-sheet inducing residues such as V, I, Y, and Q, whereas the corresponding hexapeptides in the other repeats R1 (QTAPVPM; SEQ ID NO: 20) and R4 (VEVKSE; SEQ ID NO:21) contain beta-sheet breakers such as P and E.

These observations show that the residues of tau centered around PHF6 that make up PHF43 form the backbone of PHF assembly by a limited beta-sheet interaction, while other sequences of tau remain more peripheral and retain a mostly random-coil structure. PHF43 itself forms only slender fibers, but larger constructs (e.g. K19) or full-length tau show the typical PHF-like twisted appearance; in each case the kernel of the interaction is centered around the PHF6 sequence. Without being bound by theory, several conclusions can be drawn:

(1) The sequence of PHF6 lies at the beginning of R3, just behind exon 10. It is therefore present in all tau isoforms and provides an explanation why all tau

isoforms can form PHFs. The counterpart PHF6* lies at the beginning of R2 and is therefore present only in 4-repeat isoforms. If the two hotspots for β -sheet formation operated in a cooperative fashion they could possibly enhance PHF assembly, and this might explain why PHF formation is enhanced in dementias where the 4-repeat isoforms are overrepresented (e.g. FTDP-17, see Clark *et al.*, 1998; Hutton *et al.*, 1998; Spillantini *et al.*, 1998). For example, PHF6 and PHF6* could form an intra-molecular sheet-like interaction, ready to be propagated to neighboring tau molecules. This would imply a local hairpin fold, with a bend possibly at the flexible PGGG motif at the end of R2. The occurrence of such a fold has been suggested by previous fluorescence transfer experiments involving the cysteines in repeats R2 and R3 (Schweers *et al.*, 1995).

(2) Dimerization of tau via oxidation of Cys322 into an inter-molecular disulfide bridge strongly promotes PHF assembly (Wille *et al.*, 1992). In 4R tau there are two cysteines (Cys291 in R2 and Cys322 in R3) which can either form inter-molecular bridges (Cys322-Cys322) which favors PHF assembly, or intra-molecular bridges (Cys291-C322) which locks tau in a folded conformation that is unfavorable for PHF assembly (Schweers *et al.*, 1995). Independently of that, the results shown here argue that the peptide containing Cys322 (peptide 318-335, Tab. 2) does not promote PHF assembly by itself. However, dimerization at Cys322 could bring two PHF6-motifs into close vicinity which would facilitate beta-sheet interactions. In this view, dimerization would act as an effective enhancer of local tau concentration. The close neighborhood of Cys322 and the PHF6 motif suggests that the molecules would form a parallel beta-sheet.

(3) The role of heparin or other anionic cofactors remains unknown in detail, but could effectively help reduce the repulsion between the cationic tau protein in a general way, as discussed by several authors previously (Friedhoff loc. cit., 1998a; Friedhoff loc. cit., 1998b; Goedert loc. cit., 1996; Hasegawa, J. Biol. Chem. 272 (1997), 33118-33124; Kampers, loc. cit.; Perez, loc. cit.). This would also be equivalent to enhancing the effective local concentration of tau. Heparin does not appear to change the conformation of tau by itself, as judged by the CD spectra, because a shift from random-coil to beta-structure is only observed as

polymerization progresses.

(4) In a previous study (Schweers, loc. cit.) it was described that tau is a natively unfolded protein with very little detectable secondary structure (as judged by CD, FTIR, or X-ray scattering). This conclusion still holds true (see Fig. 6a), but needs to be interpreted in more detail: The interaction leading to PHFs is based on a β -sheet structure; however, this encompasses only a small fraction of the whole sequence and therefore is not detectable by spectroscopic or scattering techniques in the full-length protein.

The presence of a β -sheet interaction also removes a previous dilemma: How could a disordered protein give rise to an ordered filament? The answer is that only a kernel of the structure needs to be ordered. The observations also explain why only the repeat domain of tau is important for PHF assembly, while the N- or C-terminal tails protrude as "fuzzy coat" (Wischik *et al.*, 1988a).

(5) In Alzheimer's disease and related tauopathies, tau is both abnormally phosphorylated and aggregated, and since phosphorylation appears to be the earlier event it was thought that phosphorylation primes tau for aggregation. However, we have shown recently that phosphorylation is antagonistic to PHF assembly, particularly the phosphorylation sites at the 3 or 4 KXGS motifs in the repeats (Ser262, 293, 324, 356, Schneider *et al.*, 1999). It is not known whether these sites interact with the PHF6 motif; but at least Ser324 is very close to the dimer-forming residue Cys322. Consistent with this, phosphorylation at KXGS motifs inhibits dimerization and thus the subsequent assembly via the PHF6 motif, in contrast to other phosphorylation sites which allow dimerization but inhibit PHF assembly at a later stage (e.g. Ser214).

(6) Tau mutations have recently been discovered for several familial frontotemporal dementias (Clark *et al.*, 1998; Hutton *et al.*, 1998; Poorkaj *et al.*, 1998; Spillantini *et al.*, 1998). Some of them are intronic mutations that affect the splicing of tau (upregulation of 4R tau); the exonic mutations cause changes or loss of residues in the repeat domain of tau. It is notable that several of these lie close to the motifs of

PHF6 (e.g. G272V in 3R-tau, P301L in 4R-tau, see Fig. 1), PHF6* (e.g. G272V in 4R-tau, N279K, Δ K280), or in an analogous position at the beginning of R4 (e.g. V337M) and could possibly enhance the ability of the mutant tau to aggregate.

EXAMPLE V

Aggregation assay of tau and tau-derived peptides and detection by tyrosine self-fluorescence (Tyrosin-Assay)

This assay is applicable particularly to the aggregation of small peptides (e.g. PHF6 as shown in SEQ ID NO: 8; K19-fragments as depicted, inter alia, in SEQ ID NO:57 or 6; K19 as shown in SEQ ID NO:10; PHF43 as depicted in SEQ ID NO:6; PHF8 as shown in SEQ ID NO:9). It can be performed in a cuvette or a 384 well plate. The assay is applicable to all tau isoforms and fragments containing Tyr310, but is particularly suitable for constructs derived from the repeat domain which contain only this one tyrosine 310, e.g. K19 (Fig. 8a), PHF43 (Fig. 8b), PHF8 (Fig. 8c) or PHF6 (Fig. 8d). This assay is based on the fact that the environment of Tyr310 changes during aggregation. As a result of the aggregation the excitation maximum of the intrinsic tyrosine fluorescence (observed at the emission maximum at 310 nm) shows a red-shift by about 5nm (e.g. from 278 to 283 nm).

Reagents for 50 μ l reaction volume:

17.5 μ l H₂O

5 μ l buffer NH₄Ac 200 mM, pH 7.0 (final concentration 20 mM)

25 μ l heparin MW 3000, 1 mM (final concentration 500 μ M)

2.5 μ l peptide (e.g. K19, PHF43, PH19, PH8, or PHF6), 10 mM (final concentration 500 μ M)

The reaction volume is placed in a fluorimeter (e.g. Fluoromax, ISA GmbH). The increase in aggregation can be measured by observing the excitation spectrum between 250 and 300 nm (Fig. 8a-d; figures show the excitation spectra before and after aggregation) at a fixed emission wavelength (310 nm).

EXAMPLE VI***Aggregation analysis of full-length-tau (isoform htau 23), fragments thereof comprising the repeat domain, PHF43 and PHF6***

Human full-length tau23 is expressed in *E. coli*, purified as described (e.g. Friedhoff, 1998a loc. cit.), and stored in 10 mM NH_4 -acetate buffer pH 7.0. The aggregation experiment is set up as follows (for 50 μl reaction volume):

35 μl H_2O

5 μl buffer NH_4 -acetate 200 mM, pH 7.0 (final concentration 20 mM)

5 μl heparin MW 3000, 500 μM (final concentration 50 μM)

5 μl tau protein 500 μM (final concentration 50 μM)

The solution is incubated at room temperature for 12 hours, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 μl reaction volume):

34 μl H_2O

5 μl buffer NH_4 -acetate, 200 mM, pH 7.0;

1 μl Thioflavine S, 100 μM (final concentration 2 μM),

10 μl tau protein from aggregation reaction (see above), 50 μM (final concentration 5 μM).

The solution is incubated for 10 min, placed in a cuvette in a fluorimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy.

Human tau fragment K19 is expressed in *E. coli*, purified as described (e.g. Friedhoff et al., 1998a), and stored in 10 mM NH_4 -acetate buffer pH 7.0. The

aggregation experiment is set up as follows (for 50 μ l reaction volume):

35 μ l H₂O

5 μ l buffer NH₄-acetate 200 mM, pH 7.0 (final concentration 20 mM)

5 μ l heparin MW 3000, 500 μ M (final concentration 50 μ M)

5 μ l K19 protein 500 μ M (final concentration 50 μ M)

The solution is incubated at room temperature for 1 hour, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 μ l reaction volume):

34 μ l H₂O

5 μ l buffer NH₄-acetate, 200 mM, pH 7.0;

1 μ l Thioflavine S, 100 μ M (final concentration 2 μ M),

10 μ l K19 protein from aggregation reaction (see above), 50 μ M (final concentration 5 μ M).

The solution is incubated for 10 min, placed in a cuvette in a fluorimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm (see examples herein above). The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy.

Human tau fragment PHF43 (SEQ ID NO: 6) is expressed in *E. coli*, purified as described above, and stored in 10 mM NH₄-acetate buffer pH 7.0. The aggregation experiment is set up as follows (for 50 μ l reaction volume):

35 μ l H₂O

5 μ l buffer NH₄-acetate 200 mM, pH 7.0 (final concentration 20 mM)

5 μ l heparin MW 3000, 500 μ M (final concentration 50 μ M)

5 μ l PHF43 protein 500 μ M (final concentration 50 μ M)

The solution is incubated at room temperature for 4 min, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 μ l reaction volume):

34 μ l H₂O

5 μ l buffer NH₄-acetate, 200 mM, pH 7.0;

1 μ l Thioflavine S, 100 μ M (final concentration 2 μ M),

10 μ l PHF43 from aggregation reaction (see above), 50 μ M (final concentration 5 μ M).

The solution is incubated for 10 min, placed in a cuvette in a fluorimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy.

Peptide PHF6 (SEQ ID NO: 8) is synthesized by standard peptide synthesis and dissolved in 10 mM NH₄-acetate buffer pH 7.0. The aggregation experiment is set up as follows (for 50 μ l reaction volume):

17.5 μ l H₂O

5 μ l buffer NH₄-acetate 200 mM, pH 7.0 (final concentration 20 mM)

25 μ l heparin MW 3000, 1 mM (final concentration 500 μ M)

2.5 μ l PHF6 peptide 10 mM (final concentration 500 μ M)

The peptide aggregates within seconds; the solution is diluted 100-fold and placed immediately into a cuvette in a fluorimeter (Fluoromax, ISA GmbH). The intrinsic tyrosine fluorescence of the peptide PHF6 is determined at an excitation wavelength of 280 nm and an emission wavelength of 310 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy. As shown herein above, wherein assays based on full-length tau or fragments comprising the repeat domain of tau require in vitro aggregation

times of at least one hour (K19 see above) or even 12 hours (full length tau, see above), assays based on PHF43 (SEQ ID NO: 6) or PHF6 (inter alia, SEQ ID NO: 8) need minimal primary incubation times of 4 min (see above in the case of PHF43) or even only seconds (see PHF6).

EXAMPLE VII

Automated screening of potential inhibitors of PHF assembly

Human tau fragment PHF43, purified as describe above and stored in 10 mM NH₄-acetate buffer pH 7.0. The aggregation experiment is set up as folllows (for 50 µl reaction volume):

35 µl H₂O

5 µl buffer NH₄-acetate 200 mM, pH 7.0 final concentration 20 mM)

5 µl heparin MW 3000, 500 µM (final concentration 50 µM)

5 µl PHF43 protein 500 µM (final concentration 50 µM)

The solution is incubated at room temperature for 1 hour, during which time the protein aggregates.

The polymerization reaction of human tau fragment PHF43 is performed in a well of a 384 well plate (Nunc).

The detection of aggregation by fluorescence is set up as follows (for 50 µl reaction volume):

34 µl H₂O

5 µl buffer NH₄-acetate, 200 mM, pH 7.0;

1 µl Thioflavine S, 100 µM (final concentration 2 µM),

10 µl PHF43 protein from aggregation reaction (see above), 50 µM (final concentration 5 µM).

For detection the samples are transferred from the incubation plate to another 384 well plate (Labsystem) with the following conditions. This 384 well plate (Labsystem) is used for measuring the ThS fluorescence with the said excitation and emission wavelengths.

The solution is incubated for 10 min., the 384 well plate is placed in a fluorimeter

(Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy.

EXAMPLE XIII

Screening for inhibitors

A typical screening using different peptides derived from a peptide phage display (NEB) using following conditions:

- a) Phage display is performed using a M-13 based system (PhD.-7 Peptide 7-mer Library Kit, New England Biosystem) with a randomized heptamer amino acid as fusion sequence to a coat protein of the phage. Enrichment of tau binding peptides from this library was performed by coating PHF43 to the surface of 96 well plates (Maxisorb, Nunc), incubation with the library and after several times of washing eluting by a 0.1 mg/ml solution of Hexapeptide VQIVYK in PBS. The eluted phages were grown up and reamplified for additional rounds of panning. After four rounds of panning phages were plated and individual clones were sequenced according to the recommendations of the supplier. Peptides of interest were synthesized by the company Eurogentech and used for the screening for inhibitory peptides for PHF formation of PHF43 and tau derived peptides seeded with PHF43 (Fig.9).

Two inhibitory peptides against the Hexapeptides PHF6 (SEQ ID NO: 7) were found. G10 and F6, which inhibit PHF formation at 200 μ M to 50 % and 30 %, respectively.

- b) The polymerization reaction of human tau fragment PHF43 is performed in a well of a 384 well plate (Nunc).
1. PHF43 final concentration 50 μ M, peptide final concentration 50 μ M

Preincubation of peptides to PHF43 30 min. at room temperature:

32.5 μ L H₂O

5 μ L PHF43, 500 μ M (final concentration 50 μ M)

2.5 μ L Peptide 1mM (final concentration 50 μ M)

5 μ L NH₄-Ac 100 mM, pH 7.0

After 30 minutes 5 μ L of heparin MW 3000, 500 μ M (final concentration 50 μ L) are added. The solution is incubated at room temperature for 1 hour, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 μ L reaction volume)

34 μ L H₂O

5 μ L buffer NH₄-Ac 200 mM, pH 7.0

1 μ L Thioflavine S, 100 μ M (final concentration 2 μ M)

10 μ L PHF protein from aggregation reaction (see above), 50 μ M (final concentration 5 μ L)

For detection the samples are transferred from the incubation plate to another 384 well plate (Labsystem). The 384 well plate (Labsystem) is used for measuring the ThS fluorescence with the said excitation and emission wavelengths.

The solution is incubated for 10 min., the 384 well plate is placed in a fluoroimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy.

2. PHF43 final concentration 50 μ M, Peptide final concentration 100 μ M

Preincubation of peptides to PHF43 30 min. at room temperature:

30 μ L H₂O

5 μ l PHF43 500 μ M (final concentration 50 mM)

5 μ l Peptid 1 mM (final concentration 100 μ M)

5 μ l $\text{NH}_4\text{-Ac}$ 100 mM, pH 7.0

After 30 minutes 5 μ l of heparin MW 3000, 500 μ M (final concentration 50 μ l) are added.

The solution is incubated at room temperature for 1 hour, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 μ l reaction volume)

34 μ l H_2O

5 μ l buffer $\text{NH}_4\text{-Ac}$ 200 mM, pH 7.0

1 μ l Thioflavine S, 100 μ M (final concentration 2 μ M)

10 μ l PHF43 protein from aggregation reaction (see above), 50 μ M (final concentration 5 μ l).

For detection the samples are transferred from the incubation plate to another 384 well plate (Labsystem). This 384 well plate (Labsystem) is used for measuring the ThS fluorescence with the said excitation and emission wavelengths.

The solution is incubated for 10 min., the 384 well plate is placed in a fluorimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy.

3. PHF43 final concentration 50 μ M, Peptide final concentration 200 μ M
Preincubation of peptides to PHF43 30 min. at room temperature:
25 μ l H_2O

50

5 μ l PHF43 500 μ M (final concentration 50 mM)

10 μ l Peptide 1 mM (final concentration 200 μ M)

5 μ l $\text{NH}_4\text{-Ac}$ 200 mM, pH 7.0

After 30 minutes 5 μ l of heparin MW 3000, 500 μ M (final concentration 50 μ l) are added.

After 30 minutes 5 μ l of heparin MW 3000, 500 μ M (final concentration 50 μ l) are added. The solution is incubated at room temperature for 1 hour, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 μ l reaction volume):

34 μ l H_2O

5 μ l buffer $\text{NH}_4\text{-Ac}$ 200 mM, pH 7.0

1 μ l Thioflavine S, 100 μ M (final concentration 2 μ M)

10 μ l PHF43 protein from aggregation reaction (see above), 50 μ M (final concentration 5 μ l).

For detection the samples are transferred from the incubation plate to another 384 well plate (Labsystem). This 384 well plate (Labsystem) is used for measuring the ThS fluorescence with the said excitation and emission wavelengths.

The solution is incubated for 10 min., the 384 well plate is placed in a fluorimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm. The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy (Fig. 9).

EXAMPLE IX***Seeding by soluble PHF43***

Human tau fragment K19 is expressed in *E. coli*, purified as described (e.g. Friedhoff et al., 1998a), and stored in 10 mM NH₄-acetate buffer pH 7.0. The aggregation experiment is set up as follows (for 50 µl reaction volume):

33,75 µl H₂O

5 µl buffer NH₄-acetate 200 mM, pH 7.0 (final concentration 20 mM)

5 µl heparin MW 3000, 500 µM (final concentration 50 µM)

5 µl K19 protein 500 µM (final concentration 50 µM)

1.25 µl PHF43 (SEQ ID NO:6) 100 µM in 10 mM NH₄-acetate buffer

The solution is incubated at room temperature for 1 hour, during which time the protein aggregates.

The detection of aggregation by fluorescence is set up as follows (for 50 µl reaction volume):

34 µl H₂O

5 µl buffer NH₄-acetate, 200 mM, pH 7.0

1 µl Thioflavine S, 100 µM (final concentration 2 µM),

10 µl K19 protein from aggregation reaction that was seeded with soluble PHF43; see above), 50 µM (final concentration 5 µM).

The solution is incubated for 10 min., placed in a cuvette in a fluorimeter (Fluoroskan Ascent, Labsystems) at room temperature. The fluorescence of Thioflavine S bound to the aggregated protein is determined at an excitation wavelength of 440 nm and an emission wavelength of 510 nm (see examples herein above). The degree of aggregation is determined by reference with a previously determined calibration series. As an additional control the presence of aggregated protein is observed by negative stain electron microscopy. Aggregation of full length tau isoforms as well as peptides derived from tau, described in the literature or disclosed here, as well as FTDP-mutations (Wilhelmsen (1999) loc. cit.) of tau can equally be seeded with soluble PHF43 (SEQ ID NO: 6) and speeded up and analyzed as described above.

Claims

1. A method for identifying and obtaining an inhibitor, capable of modifying the PHF formation comprising the steps of
 - (a) incubating a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 and 9 or (a) fragment(s) thereof, with a compound to be screened under conditions which permit assembly of said tau-derived peptides into nucleation sites for PHF assembly and/or into aggregation products; and
 - (b) detecting the presence, decrease, or absence of nucleation sites for PHF assembly and/or the presence, decrease or absence of aggregation products wherein said absence and/or decrease is indicative for putative inhibitors for PHF formation.
2. The method of claim 1 wherein in step (a) said incubation is carried out in the presence of assembly-competent tau protein(s) and/or assembly-competent tau protein fragments and wherein in step (b) the presence, decrease and/or absence of PHF or tau filaments is detected.
3. A method for identifying and obtaining an inhibitor of PHF formation comprising the steps of:
 - (a) contacting a peptide comprising a specific tau-derived peptide as defined in any one of SEQ ID NOs. 6, 7, 8 or 9 or (a) fragment(s) thereof with the first molecule known to bind to said peptide to form a first complex of said peptide and said first molecule;
 - (b) contacting said first complex with a compound to be screened; and
 - (c) measuring whether said compound displaces said first molecule from said first complex.
4. The method of claim 3 wherein said measuring step (c) comprises the measurement of a formation of a second complex of said tau-derived peptide and said compound.

5. The method of claim 3 or 4 wherein said measuring step (c) comprises the measurement of the amount of said first molecule that is not bound to said tau-derived peptide.
6. A method for the preparation of a pharmaceutical composition comprising the steps of a method of any one of claims 1 to 5; and synthesizing and/or formulating the compounds identified, obtained and/or screened in step (b) or derivative thereof in a pharmaceutically acceptable form.
7. The method of any one of claims 1 to 6 wherein said peptide comprising a tau-derived peptide is bound to a solid phase.
8. The method of any one of claims 1 to 7, wherein said incubation step is carried out in the presence of (poly)anions.
9. An inhibitor identified or obtained by the method of any one of claims 1 to 8.
10. The inhibitor of claim 9 which specifically binds to a peptide comprising the tau-derived peptides as defined in any one of SEQ ID NOs. 6, 7, 8 or 9 or (a) fragment thereof.
11. The inhibitor of claim 9 or 10 which is an antibody, an aptamer or a small molecule peptide.
12. The inhibitor of claim 11 which is a monoclonal antibody.
13. A composition comprising the inhibitor as identified or obtained by the method of any one of claims 1 to 8 or the inhibitor of any one of claims 9 to 12.
14. The composition of claim 13 which is a diagnostic or a pharmaceutical composition further comprising, optionally, suitable means of detection and/or pharmaceutically acceptable carrier, excipient and/or diluent.

15. A method for detecting and/or measuring PHF formation comprising the steps of:
 - (a) incubating a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs. 6, 7, 8 or 9 or (a) fragment(s) thereof, with tau-protein(s) and/or fragments thereof under conditions which permit assembly of tau-proteins and/or fragments thereof into PHFs; and
 - (b) detecting the presence, absence, decrease or increase of PHFs and/or nucleation sites of PHF assembly.
16. The method of any one of claims 1 to 8 or 15, wherein said detection or measuring step is carried out by microscopical or spectroscopical means.
17. The method of claim 16 wherein said microscopical means comprises electron microscopy.
18. The method of claim 16 wherein said spectroscopical means comprises circular dichroism spectroscopy or fluorescence spectroscopy, or infrared spectroscopy.
19. The method of claim 18, wherein said fluorescence spectroscopy comprises a thioflavin S or T assay or a tyrosine self-fluorescence assay.
20. A kit comprising at least one of the following:
 - (a) a peptide comprising a specific tau derived peptide as defined in any one of SEQ ID NOs 6, 7, 8 or 9 or (a) fragment(s) thereof and/or a nucleic acid molecule encoding said peptide or (a) fragment(s) thereof;
 - (b) tau-protein(s) and/or fragments thereof as defined in claims 2 and/or 15;
 - (c) a solid support as defined in claim 7;adopted for carrying out the method of claims 1 to 8 and/or 15 to 19 optionally further comprising a standard and or suitable means for detection.

21. A kit comprising an inhibitor as defined in any one of claims 9 to 12 or a composition as defined in claim 13 or 14.
22. Use of the kit of claim 20 for carrying out the method of any one of claims 1 to 8 and/or 15 to 19.
23. Use of a peptide comprising a specific tau derived peptide as defined in SEQ ID Nos. 6, 7, 8 and/or 9, or a nucleic acid molecule encoding a specific tau derived peptide as defined in SEQ ID NOS. 6, 7, 8 and/or 9 for carrying out the method of any one of claims 1 to 8 and/or 15 to 19.
24. Use of a peptide comprising a specific tau derived peptide as defined in SEQ ID Nos. 6, 7, 8 and/or 9, or a nucleic acid molecule encoding a specific tau derived peptide as defined in SEQ ID NOS. 6, 7, 8 and/or 9 for screening and/or for the identification of an inhibitor, capable of modifying PHF formation.
25. The use of claims 23 or 24 or the method of any one of claims 1 to 6 and 15 wherein said peptide comprising a specific tau derived peptide as defined in SEQ ID NOS. 6, 7, 8 and/or 9 is expressed in a non-human transgenic animal, a tissue culture and/or a cell culture system.
26. The use of any one of claims 23 to 25 or the method of any one of claims 1 to 6, 13 and 25 wherein said peptide comprising a specific tau derived peptide as defined in SEQ ID NOS 6, 7, 8 and/or 9 further comprises in the hexapeptide as defined in SEQ ID NOS 7 or 8 at least one mutation/modification.
27. The use or the method of claim 26, wherein said mutation and/or modification comprises the replacement of at least one amino acid with high intrinsic β -sheet propensity with at least one amino acid with low or no intrinsic β -sheet propensity.

Abstract

The present invention relates to a method for identifying and obtaining an inhibitor, capable of modifying the PHF ("paired helical filaments") formation comprising the steps of (a) incubating a peptide comprising a specific tau derived peptide as defined herein or a fragment(s) thereof with a compound to be screened under conditions which permit assembly of said tau-derived peptides into nucleation sites for PHF assembly and/or into aggregation products; and (b) detecting the presence, decrease, or absence of nucleation sites for PHF assembly and/or the presence, decrease or absence of said aggregation products wherein said absence and/or decrease is indicative for putative inhibitors for PHF formation. Furthermore, the present invention provides inhibitors identified or obtained by said method as well as compositions comprising said inhibitor, wherein said composition is preferably a diagnostic and/or a pharmaceutical composition. The present invention further relates to a method for detecting and/or measuring PHF formation comprising the steps of (a) incubating a peptide comprising a specific tau derived peptide as defined herein or (a) fragment(s) thereof, with tau-proteins and/or fragments thereof under conditions which permit assembly of tau-proteins and/or fragments thereof into PHFs; and (b) detecting the presence, absence, decrease or increase of PHFs and/or nucleation sites of PHF assembly. Additionally, the present invention provides for kits and uses for carrying out the method of the present invention.




Figure 1

Assembly kinetics of PHF43, K19, htau23 (20 μ M)




Figure 2

K19 derived peptides and their ability for PHF assembly

Sample	Sequence	Aggr.
K19	Q244...PGGGK QIVYK PV...N368	+
K19-Mut.	Q244...PGGGK---VYKPV...N368	-
	Q244...PGGGKNAEVYKPV...N368	-
	Q244...PGGGK QIV VEKPV...N368	-
K19/ Chym.	Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368	-
K19/ Gluc pH 4.0	Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368	-
K19/ Gluc pH 7.8	Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368 Q244...PGGGK QIVYK PV...N368	-
PHF8	Q244...PGGGK QIVYK PV...N368	*
PHF6	Q244...PGGGK QIVYK PV...N368	*
V ₃₁₃ -K ₃₂₁	Q244...PGGGK QIVYK PV...N368	-
V ₃₁₈ -G ₃₃₅	Q244...PGGGK QIVYK PV...N368	-
G ₃₃₅ -E ₃₄₂	Q244...PGGGK QIVYK PV...N368	-

Figure 3

19-12-2000

00965965.7 EP00/08863

DRAW

4/22



Figure 4a

19-12-2000

00965965 7 EP00/08863

DRAW

5/22



Figure 4b

19-12-2000

00965965.7-EP00/08863

DFAW

6/22




Figure 4c

19-12-2000

00965965 7 - EP00/08863

DRAW

7/22




Figure 4d

ART 34 AMDT

Printed:09-04-2001

19-12-2000

00965965.7- EP00/08863

DRAW

8/22



Figure 4e

ART 34 AMDT

19-12-2000

00965965.7 - EP00/08863

DRAW

9/22



Figure 4f

Binding of PHF1-43 to a peptide library of htau40 (R2-R3)




Figure 5

**htau23 Monomer and Dimer in the presence or
absence of heparin and htau23 PHF's**





Figure 6a

K19 Monomer and Dimer in the presence or absence of heparin and K19-PHF's



- K19 Monomer + heparin
- K19 Monomer
- ▼ K19 Dimer + heparin
- ▽ K19 Dimer

— K19PHF

Figure 6b

PHF43 Monomer and Dimer in the presence or absence of Heparin





Figure 6c

**PHF8 (G₂₇₃KVQIVYK) and PHF6 (V₃₀₆QIVYK)
in the presence or absence of heparin**





Figure 6d

**V₃₁₃DLSKVTSK₃₂₁, V₃₁₈TSKCGSLGNIHHPGGG₃₃₅,
G₃₃₅QVEVKSE₃₄₂ in the presence and absence
of heparin**



- V₃₁₃DLSKVTSK₃₂₁ + heparin
- V₃₁₃DLSKVTSK₃₂₁
- ▼ V₃₁₈TSKCGSLGNIHHPGGG₃₃₅ + heparin
- ▽ V₃₁₈TSKCGSLGNIHHPGGG₃₃₅
- G₃₃₅QVEVKSE₃₄₂ + heparin
- G₃₃₅QVEVKSE₃₄₂

Figure 6e

K19 and PHF43 Dimer and PHF in 50% TFE





Figure 6f

Estimate of secondary structure content

Sample	Alpha helix	Beta sheet	Random coil
htau23 Monomer	13,6	18,3	68,1
htau23 Monomer + Heparin	14,3	20,0	65,7
htau23 Dimer	18,8	8,8	72,4
htau23 Dimer + Heparin	7,6	12,3	80,1
htau23 PHF	8,3	15,4	76,3
htau23 Dimer 50% TFE	62,4	6,4	31,2
htau23 PHF 50% TFE	65,2	10,3	24,5
K19 Monomer	12,1	21,5	66,4
K19 Monomer + hep.	28,1	1,7	70,2
K19 Dimer	13,0	13,6	73,4
K19 Dimer + hep.	2,3	22,4	75,3
K19 PHF	5,2	36,8	58,0
K19 Dimer 50 % TFE	67,2	32,8	0,0
K19 PHF 50 % TFE	34,0	32,2	33,8
PHF43 Monomer	6,6	24,7	68,7
PHF43 Monomer + hep.	9,0	30,4	60,6
PHF43 Dimer	4,3	23,2	72,5
PHF43 Dimer + hep. (PHF)	0,0	55,2	44,8
PHF43 Dimer 50% TFE	38,5	27,3	34,2
PHF43 PHF 50% TFE	9,4	48,3	42,3
GKVQIVYK	8,2	23,7	68,1
GKVQIVYK + hep.	5,4	33,1	61,5
VQIVYK	17,1	5,7	77,2
VQIVYK +hep.	6,6	58,1	35,3
VDLSKVTSK	5,2	22,7	72,1
VDLSKVTSK + hep.	0,0	29,9	70,1
VTSKCGSLGNIHHKPGGG	15,2	22,7	62,1
VTSKCGSLGNIHHKPGGG + hep.	13,5	29,9	56,6
GQVEVKSE	0,0	25,3	74,7
GQVEVKSE + hep.	8,8	22,7	68,5

Figure 7

K19 Excitation-Spectrum




Figure 8a

PHF43 Excitation-Spectrum




Figure 8b

Title: A MINIMAL TAU PEPTIDE
FOR THE NUCLEATION OF
PAIRED HELICAL FILAMENTS
Inventor(s): von Bergen et al.
DOCKET NO.: 029976-0101

20/22

10/070611 10/070611

PHF8 Excitation-Spectrum




Figure 8c

PHF6 Excitation-Spectrum




Figure 8d

22/22

Screening for inhibitory peptides against K19
aggregation seeded by PHF43




Fig. 9

SEQUENCE LISTING

<110> VON BERGEN, Martin
 BIERNAT, Jacek
 MANDELKOW, Eva-Maria
 MANDELKOW, Eckhard

<120> A MINIMAL TAU PEPTIDE FOR THE NUCLEATION OF PAIRED HELICAL FRAGMENTS

<130> 029976/0101

<140> US 10/070611

<141> 2000-09-11

<150> PCT/EP00/08863

<151> 2000-09-11

<150> EP 99117805.4

<151> 1999-09-09

<160> 62

<170> PatentIn version 3.1

<210> 1

<211> 125

<212> PRT

<213> Homo sapiens

<400> 1

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 1 5 10 15

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 20 25 30

Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 35 40 45

Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 50 55 60

Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 65 70 75 80

Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 85 90 95

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 100 105 110

Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
 115 120 125

<210> 2
 <211> 31
 <212> PRT
 <213> Homo sapiens

<400> 2

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 1 5 10 15

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys
 20 25 30

<210> 3
 <211> 31
 <212> PRT
 <213> Homo sapiens

<400> 3

Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys
 1 5 10 15

Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser
 20 25 30

<210> 4
 <211> 31
 <212> PRT
 <213> Homo sapiens

<400> 4

Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys
 1 5 10 15

Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln
 20 25 30

<210> 5
 <211> 32
 <212> PRT
 <213> Homo sapiens

<400> 5

Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser
 1 5 10 15

Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
 20 25 30

<210> 6
 <211> 43
 <212> PRT
 <213> Homo sapiens

<400> 6

Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val Gln Ile Val Tyr Lys
 1 5 10 15

Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly Ser Leu Gly Asn
 20 25 30

Ile His His Lys Pro Gly Gly Gly Gln Val Glu
 35 40

<210> 7
 <211> 6
 <212> PRT
 <213> Homo sapiens

<400> 7

Val Gln Ile Ile Asn Lys
 1 5

<210> 8
 <211> 6
 <212> PRT
 <213> Homo sapiens

<400> 8

Val Gln Ile Val Tyr Lys
 1 5

<210> 9
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 9

Gly Lys Val Gln Ile Val Tyr Lys
 1 5

<210> 10
 <211> 94
 <212> PRT
 <213> Homo sapiens

<400> 10

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 1 5 10 15

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 20 25 30

Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys
 35 40 45

Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu
 50 55 60

Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile
 65 70 75 80

Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
 85 90

<210> 11
 <211> 94
 <212> PRT
 <213> Homo sapiens

<400> 11

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 1 5 10 15

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Asn
 20 25 30

Ala Glu Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys
35 40 45

Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu
50 55 60

Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile
65 70 75 80

Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
85 90

<210> 12
<211> 91
<212> PRT
<213> Homo sapiens

<400> 12

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
1 5 10 15

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
20 25 30

Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly Ser Leu
35 40 45

Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val Lys Ser
50 55 60

Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly Ser Leu
65 70 75 80

Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
85 90

<210> 13
<211> 94
<212> PRT
<213> Homo sapiens

<400> 13

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
 1 5 10 15

Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 20 25 30

Gln Ile Val Glu Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys
 35 40 45

Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu
 50 55 60

Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile
 65 70 75 80

Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
 85 90

<210> 14

<211> 9

<212> PRT

<213> Homo sapiens

<400> 14

Val Asp Leu Ser Lys Val Thr Ser Lys
 1 5

<210> 15

<211> 18

<212> PRT

<213> Homo sapiens

<400> 15

Val Thr Ser Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly
 1 5 10 15

Gly Gly

<210> 16
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 16

Gly Gln Val Glu Val Lys Ser Glu
 1 5

<210> 17
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 17

Val Asp Leu Ser Lys Val Thr Ser Lys
 1 5

<210> 18
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 18

Val Thr Ser Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly
 1 5 10 15

Gly Gly

<210> 19
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 19

Gly Gln Val Glu Val Lys Ser Glu
 1 5

<210> 20
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 20

Gln Thr Ala Pro Val Pro Met
1 5

<210> 21

<211> 6

<212> PRT

<213> Homo sapiens

<400> 21

Val Glu Val Lys Ser Glu
1 5

<210> 22

<211> 15

<212> PRT

<213> Homo sapiens

<400> 22

Leu Lys Asn Val Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys
1 5 10 15

<210> 23

<211> 15

<212> PRT

<213> Homo sapiens

<400> 23

Val Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro
1 5 10 15

<210> 24

<211> 15

<212> PRT

<213> Homo sapiens

<400> 24

Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly
1 5 10 15

<210> 25

<211> 15

<212> PRT

<213> Homo sapiens

<400> 25

Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val Gln
1 5 10 15

<210> 26

<211> 15

<212> PRT

<213> Homo sapiens

<400> 26

Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val Gln Ile Ile Asn
1 5 10 15

<210> 27

<211> 15

<212> PRT

<213> Homo sapiens

<400> 27

His Gln Pro Gly Gly Gly Lys Val Gln Ile Ile Asn Lys Lys Leu
1 5 10 15

<210> 28

<211> 15

<212> PRT

<213> Homo sapiens

<400> 28

Gly Gly Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser
1 5 10 15

<210> 29

<211> 15

<212> PRT

<213> Homo sapiens

<400> 29

Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln
1 5 10 15

<210> 30

<211> 15

<212> PRT

<213> Homo sapiens

<400> 30

Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
1 5 10 15

<210> 31

<211> 15

<212> PRT

<213> Homo sapiens

<400> 31

Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys Gly Ser Lys
1 5 10 15

<210> 32

<211> 15

<212> PRT

<213> Homo sapiens

<400> 32

Asp Leu Ser Asn Val Gln Ser Lys Cys Gly Ser Lys Asp Asn Ile
1 5 10 15

<210> 33

<211> 15

<212> PRT

<213> Homo sapiens

<400> 33

Asn Val Gln Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val
1 5 10 15

<210> 34

<211> 15

<212> PRT

<213> Homo sapiens

<400> 34

Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly
1 5 10 15

<210> 35

<211> 15

<212> PRT

<213> Homo sapiens

<400> 35

Gly	Ser	Lys	Asp	Asn	Ile	Lys	His	Val	Pro	Gly	Gly	Gly	Ser	Val
1				5					10					15

<210> 36

<211> 15

<212> PRT

<213> Homo sapiens

<400> 36

Asp	Asn	Ile	Lys	His	Val	Pro	Gly	Gly	Gly	Ser	Val	Gln	Ile	Val
1				5					10					15

<210> 37

<211> 15

<212> PRT

<213> Homo sapiens

<400> 37

Lys	His	Val	Pro	Gly	Gly	Gly	Ser	Val	Gln	Ile	Val	Tyr	Lys	Pro
1				5					10					15

<210> 38

<211> 15

<212> PRT

<213> Homo sapiens

<400> 38

Pro	Gly	Gly	Gly	Ser	Val	Gln	Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu
1				5					10					15

<210> 39

<211> 15

<212> PRT

<213> Homo sapiens

<400> 39

Gly	Ser	Val	Gln	Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu	Ser	Lys	Val
1				5					10					15

<210> 40

<211> 15

<212> PRT

<213> Homo sapiens

<400> 40

Gln	Ile	Val	Tyr	Lys	Pro	Val	Asp	Leu	Ser	Lys	Val	Thr	Ser	Lys
1				5					10					15

<210> 41

<211> 15

<212> PRT

<213> Homo sapiens

<400> 41

Tyr	Lys	Pro	Val	Asp	Leu	Ser	Lys	Val	Thr	Ser	Lys	Cys	Gly	Ser
1				5					10					15

<210> 42

<211> 15

<212> PRT

<213> Homo sapiens

<400> 42

Val	Asp	Leu	Ser	Lys	Val	Thr	Ser	Lys	Cys	Gly	Ser	Leu	Gly	Asn
1				5					10					15

<210> 43

<211> 15

<212> PRT

<213> Homo sapiens

<400> 43

Ser	Lys	Val	Thr	Ser	Lys	Cys	Gly	Ser	Leu	Gly	Asn	Ile	His	His
1				5					10					15

<210> 44

<211> 15

<212> PRT

<213> Homo sapiens

<400> 44

Thr	Ser	Lys	Cys	Gly	Ser	Leu	Gly	Asn	Ile	His	His	Lys	Pro	Gly
1				5					10					15

<210> 45

<211> 15

<212> PRT

<213> Homo sapiens

<400> 45

Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln
1 5 10 15

<210> 46

<211> 15

<212> PRT

<213> Homo sapiens

<400> 46

Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
1 5 10 15

<210> 47

<211> 15

<212> PRT

<213> Homo sapiens

<400> 47

Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val Lys Ser Glu
1 5 10 15

<210> 48

<211> 15

<212> PRT

<213> Homo sapiens

<400> 48

Lys Pro Gly Gly Gly Gln Val Glu Val Lys Ser Glu Lys Leu Asp
1 5 10 15

<210> 49

<211> 15

<212> PRT

<213> Homo sapiens

<400> 49

Gly Gly Gln Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp
1 5 10 15

<210> 50

<211> 15

<212> PRT

<213> Homo sapiens

<400> 50

Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln
1 5 10 15

<210> 51

<211> 15

<212> PRT

<213> Homo sapiens

<400> 51

Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile
1 5 10 15

<210> 52

<211> 21

<212> PRT

<213> Homo sapiens

<400> 52

Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys
1 5 10 15

Ile Gly Ser Thr Glu
20

<210> 53

<211> 4

<212> PRT

<213> Homo sapiens

<400> 53

Val Lys Ser Glu
1

<210> 54

<211> 26

<212> PRT

<213> Homo sapiens

<400> 54

Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly Ser Leu Asp
1 5 10 15

Asn Ile Thr His Val Pro Gly Gly Gly Asn
20 25

<210> 55
<211> 9
<212> PRT
<213> Homo sapiens

<400> 55

Gln Thr Ala Pro Val Pro Met Pro Asp
1 5

<210> 56
<211> 12
<212> PRT
<213> Homo sapiens

<400> 56

Leu Lys Asn Val Lys Ser Lys Ile Gly Ser Thr Glu
1 5 10

<210> 57
<211> 19
<212> PRT
<213> Homo sapiens

<400> 57

Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val Gln Ile Val Tyr Lys
1 5 10 15

Pro Val Asp

<210> 58
<211> 24
<212> PRT
<213> Homo sapiens

<400> 58

Leu Ser Lys Val Thr Ser Lys Cys Gly Ser Leu Gly Asn Ile His His
1 5 10 15

Lys Pro Gly Gly Gly Gln Val Glu
20

<210> 59
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 59

Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile
 1 5 10 15

Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
 20 25 30

<210> 60
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 60

Gly Lys Val Tyr Lys Pro Val
 1 5

<210> 61
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 61

Gly Lys Asn Ala Glu Val Tyr Lys Pro Val
 1 5 10

<210> 62
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 62

Gly Lys Val Gln Ile Val Glu Lys Pro Val
 1 5 10

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A MINIMAL TAU PEPTIDE FOR THE NUCLEATION OF PAIRED HELICAL FILAMENTS

(Attorney Docket No. 029976-0101)

the specification of which (check one)

 is attached hereto.

 X was filed on September 11, 2000 as United States Application Number or PCT International Application Number PCT/EP00/08863 and was amended on (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

Atty. Dkt. No. 029976-0101

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
99 11 7805.4	E.P.C.	09/09/1999	YES	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the registered attorneys and agents at Customer Number 22428



22428

PATENT TRADEMARK OFFICE

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

Atty. Dkt. No. 029976-0101

I request that all correspondence be directed to:

Richard C. Peet
 FOLEY & LARDNER
 Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5483
 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1-00	Name of first inventor	<u>Martin von Bergen</u>
	Residence	<u>Gulzow, Federal Republic of Germany</u>
	Citizenship	<u>German</u> <u>DE</u>
	Post Office Address	<u>Geesthachter Strasse 40</u> <u>21483 Gulzow</u> <u>Federal Republic of Germany</u>
	Inventor's signature	<u><i>M. von Bergen</i></u>
	Date	<u>17/05/02</u>
2-00	Name of second inventor	<u>Jacek Biernat</u>
	Residence	<u>Schenefeld, Federal Republic of Germany</u> <u>DE</u>
	Citizenship	<u>German</u>
	Post Office Address	<u>Blockhorner Weiden 8</u> <u>22869 Schenefeld</u> <u>Federal Republic of Germany</u> <u>/</u>
	Inventor's signature	<u><i>J. Biernat</i></u>
	Date	<u>17-05-2002</u>

Atty. Dkt. No. 029976-0101

Name of third inventor

Eva-Maria Mandelkow

Residence

Hamburg, Federal Republic of Germany

Citizenship

German DEX

Post Office Address

Baron-Voght-Strasse 212a22607 HamburgFederal Republic of Germany

Inventor's signature

S. Mandelkow

Date

17.05.02

Name of fourth inventor

Eckhard Mandelkow

Residence

Hamburg, Federal Republic of Germany

Citizenship

German DEX

Post Office Address

Baron-Voght-Strasse 212a22607 HamburgFederal Republic of Germany


Inventor's signature

Mandelkow

Date

17. May 2002

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available. Some figures are done.*